Novel ARYL ether-substituted heterocyclic compounds as GLP1r agonists
Novel aryl ether-substituted heterocyclic compounds address the limitations of existing GLP1R agonists by offering improved oral bioavailability and pharmacokinetics, enhancing treatment options for obesity, diabetes, and fatty liver diseases.
Patent Information
- Application Number
- CA3224598
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-09-29
- Filing Date
- 2022-01-31
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-01-31
AI Technical Summary
Current GLP1R agonist peptides for treating obesity, diabetes, and fatty liver diseases require injection, have poor compliance, high cost, and are difficult to combine with oral small molecule drugs, while existing small-molecule GLP1 agonists like PF-06882961 suffer from poor oral absorption, low bioavailability, and gastrointestinal toxicity.
Development of novel aryl ether-substituted heterocyclic compounds with GLP1R agonistic activity, exhibiting improved pharmacokinetics and bioavailability, suitable for oral administration.
The compounds demonstrate better human PK and bioavailability than reference compounds, making them suitable candidates for treating diseases related to the GLP1/GLP1R pathway with reduced gastrointestinal toxicity.
Abstract
Description
NOVEL ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS This application claims the priority of the previous applications submitted to the State Intellectual Property Office of China on August 30, 2021, with the patent application number of 202111017657.5 and the name of "novel aromatic ether substituted heterocyclic compound as GLP1R agonist" and submitted to the State Intellectual Property Office of China on September 29, 2021 with the patent application number of 202111168512.5 and the name of "novel aromatic ether substituted heterocyclic compound as GLP1R agonist". TECHNICAL FIELD The invention belongs to the field of medicinal chemistry, specifically comprising novel aryl ether substituted heterocyclic compounds having GLP1R agonistic activity, compositions comprising the class of compounds and methods for applying the class of compounds to the preparation of drugs for the treatment or prevention of diseases associated with GLP1 / GLP1R. BACKGROUND OF THE INVENTION With the improvement of living standards, overweight or obesity is becoming more and more common in modern society. The number of patients with obesity related complications such as diabetes and fatty liver is increasing. Reports from the World Health Organization (WHO) and ZhiYan advisory predict that the number of obese patients in the world will reach 3.26 billion by 2030; By 2029, the number of global patients with diabetes will exceed 500 million; The number of patients with nonalcoholic fatty liver disease in the world will exceed 1.5 billion. At present, there is no effective drug for fatty liver; There are only 6 drugs approved by FDA for the treatment of obesity, and most of them are controlled drugs with weak efficacy and strong side effects; Although many drugs for the treatment of type 2 diabetes have been approved for marketing, achieved optimal diabetes control-rate (HbA1c <com:Math><semantics><7%<annotation encoding="application / x-tex">< 7\%< / annotation>< / semantics>< / com:Math>), and the achieved optimal diabetes control-rate of even the most active combination drug is only about 45%. Therefore, for fatty liver, obesity or diabetes, new drugs need to be developed to meet the unmet needs of more patients. Glucagon-like peptide-1 (GLP-1) is a long peptide hormone containing 30 or 31 amino acids. It is produced and secreted by enteroendocrine L cells and certain neurons in the nucleus tractus solitarius of the brainstem during feeding. GLP-1 stimulates insulin secretion, reduces glucagon secretion, inhibits gastric emptying, reduces appetite, and stimulates beta cell proliferation in a physiological and glucose-dependent manner. In non-clinical experiments, GLP-1 promotes β-cell persistence by stimulating transcription of genes important for glucose- dependent insulin secretion and promoting <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-cell regeneration (Meier, et al. Biodrugs. 2003; 17(2): 93 -102). The GLP1 receptor is a proven ideal target for the treatment of metabolic diseases such as obesity, diabetes, fatty liver, etc., and several GLP1R agonist peptide drugs such as dulaglutide, somalutamide have been approved abroad for the treatment of diabetes and weight loss. However, these peptides need to be injected with poor compliance, high cost, poor accessibility, and heavy social medical burden. These peptides need to be refrigerated, which is inconvenient to carry and store. In addition, these peptides are difficult for combination use with existing oral small molecule drugs for diseases having complex causes and requiring treatment of multiple drug combinations, such as nonalcoholic fatty liver disease. Therefore, there is an urgent need to develop small-molecule oral GLP1R agonists. Oral small molecule GLP1 agonists have been reported in a few literatures or patents: for example, Pfizer's PF-06882961 can achieve similar or better efficacy as GLP1 polypeptides (https: / / doi.org / 10.1101 / 2020.09.29.319483). Although the efficacy and safety have been preliminarily verified, PF-06882961 has some druggability deficiencies, such as poor oral absorption, extremely low bioavailability, high clinical dosage, and heavy burden on gastrointestinal tract of patients (GI toxicity), which cannot achieve better glucose - and weight- lowering effect by further increasing the drug amount, and so on. Therefore, it is necessary to develop new small-molecule GLP1 agonists with better druggabilities to meet the needs of more patients. TECHNICAL EFFECTS The inventors unexpectedly found that some of the novel aryl ether-substituted heterocyclic compounds of formula (I) of the present invention not only have significant GLP1R agonistic activity, but also have better pharmacokinetics parameters (including longer T1 / 2, higher exposure) and bioavailability than the reference compound PF-06882961 with a known structure. These compounds are expected to have better human PK, and are more suitable as drug candidates for preventing or treating diseases related to GLP1 / GLP1R target or signaling pathway. SUMMARY OF INVENTION The object of the present invention is to provide the compound represented by Formula (I) or its pharmaceutically acceptable salt, solvate, enantiomer and isotopic variations thereof. [Image disponible dans le document PDF, Image available in the PDF document] Formula (I) Wherein, Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures; X and X' are each independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)N(Rd3)<annotation encoding="application / x-tex">-C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=NRd5)<annotation encoding="application / x-tex">C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(Rd6)<annotation encoding="application / x-tex">-S(=O)_2N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; X<com:Sub>1< / com:Sub>, X<com:Sub>2< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>4< / com:Sub>, X<com:Sub>5< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>9< / com:Sub> are each independently selected from–CR<com:Sub>5< / com:Sub>- or - N-; R<com:Sub>0< / com:Sub> is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R<com:Sub>0< / com:Sub> representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally optimally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate, preferably, the carboxyl [Image disponible dans le document PDF, Image available in the PDF document] surrogate ; Wherein <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> 10 alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkylcarboxyl or carboxyl surrogates are optionally optimally substituted with one to more substituents selected from H, deuterium, halogen, OCH<com:Sub>3< / com:Sub>, Carboxyl, OH, CN and NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>; Or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, <com:Math><semantics>=<annotation encoding="application / x-tex">=< / annotation>< / semantics>< / com:Math>O, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-6< / com:Sub> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> and R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkylamino, N, N- <com:Math><semantics>di(C1−10 alkyl)<annotation encoding="application / x-tex">di(C_{1-10} \text{ alkyl})< / annotation>< / semantics>< / com:Math>amino, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylacyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylacyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylsulfonyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylsulfonyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkylsulfinyl, C<com:Sub>3-10< / com:Sub> cycloalkylamino, C<com:Sub>3-10< / com:Sub> heterocycloalkylamino, C<com:Sub>3-10< / com:Sub> cycloalkoxy, C<com:Sub>3-10< / com:Sub> cycloalkylacyl, C<com:Sub>3-10< / com:Sub> cycloalkoxyacetyl, C<com:Sub>3-10< / com:Sub> cycloalkylsulfonyl and C<com:Sub>3-10< / com:Sub> cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(<com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-6< / com:Sub> alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Or optionally R<com:Sub>2< / com:Sub> and R<com:Sub>2'< / com:Sub> or R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> are the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- heteroaryl, 3- to 8- saturated or partially saturated cycloalkyl, 3- to 8- saturated or partially saturated heterocyclyl, and wherein the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-6< / com:Sub> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; R<com:Sub>d3< / com:Sub>, R<com:Sub>d4< / com:Sub>, R<com:Sub>d5< / com:Sub>, R<com:Sub>d6< / com:Sub>, R<com:Sub>d7< / com:Sub>, R<com:Sub>d8< / com:Sub>, R<com:Sub>d9< / com:Sub> and R<com:Sub>d10< / com:Sub> are the same or different, and are optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> 10 alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> 10 heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; the hetero represents any heteroatom optionally and independently selected from O, N, S, P and isotopes thereof; the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IA), [Image disponible dans le document PDF, Image available in the PDF document] Formula (IA) Wherein, Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures; X and X' are each independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)N(Rd3)<annotation encoding="application / x-tex">-C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> [Image disponible dans le document PDF, Image available in the PDF document] L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; X<com:Sub>1< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>9< / com:Sub> are each independently selected from –CR<com:Sub>5< / com:Sub>- or - N-; R<com:Sub>0< / com:Sub> is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein <com:Math><semantics>R0<annotation encoding="application / x-tex">R_0< / annotation>< / semantics>< / com:Math> representing <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally optimally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally optimally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> Alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate, preferably, the [Image disponible dans le document PDF, Image available in the PDF document] carboxyl surrogate ; Wherein <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-< / com:Sub> 10 heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkylcarboxyl or carboxyl surrogates are optionally optimally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH<com:Sub>3< / com:Sub>, Carboxyl, OH, CN and NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>; Or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, <com:Math><semantics>=<annotation encoding="application / x-tex">=< / annotation>< / semantics>< / com:Math>O, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> and R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkylamino, N, N- <com:Math><semantics>di(C1−10 alkyl)<annotation encoding="application / x-tex">di(C_{1-10} \text{ alkyl})< / annotation>< / semantics>< / com:Math>amino, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylacyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylacyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylsulfonyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylsulfonyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkylsulfinyl, C<com:Sub>3-10< / com:Sub> cycloalkylamino, C<com:Sub>3-10< / com:Sub> heterocycloalkylamino, C<com:Sub>3-10< / com:Sub> cycloalkoxy, C<com:Sub>3-10< / com:Sub> cycloalkylacyl, C<com:Sub>3-10< / com:Sub> cycloalkoxyacetyl, C<com:Sub>3-10< / com:Sub> cycloalkylsulfonyl and C<com:Sub>3-10< / com:Sub> cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Or optionally R<com:Sub>2< / com:Sub> and R<com:Sub>2'< / com:Sub> or R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each Rd3, Rd4, Rd5, Rd6, Rd7, Rd8, Rd9 and Rd10 is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> <com:Sub>10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-< / com:Sub> 10 heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. 2 In one embodiment of the present invention, the compound or a pharmaceutically 3 acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IB), [Image disponible dans le document PDF, Image available in the PDF document] Formula (IB) Wherein, Ring B is optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures; X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)N(Rd3)<annotation encoding="application / x-tex">-C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=NRd5)<annotation encoding="application / x-tex">C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(Rd6)<annotation encoding="application / x-tex">-S(=O)_2N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math>; L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; X<com:Sub>1< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>8< / com:Sub>, X<com:Sub>9< / com:Sub> X<com:Sub>10< / com:Sub>, X<com:Sub>11< / com:Sub> and X<com:Sub>12< / com:Sub> are independently selected from –CR<com:Sub>5< / com:Sub>- or - N-; R<com:Sub>0< / com:Sub> is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R<com:Sub>0< / com:Sub> representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, carboxyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> Alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate, preferably, the [Image disponible dans le document PDF, Image available in the PDF document] carboxyl surrogate ; Wherein C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl substituted by <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl or <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> 10 heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more groups selected from H, deuterium, Halogen, OCH<com:Sub>3< / com:Sub>, Carboxyl, OH, CN and NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>; Or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(<com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl)<com:Sub>2< / com:Sub>, =O, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-6< / com:Sub> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> and R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkylamino, N, N- <com:Math><semantics>di(C1−10 alkyl)<annotation encoding="application / x-tex">di(C_{1-10} \text{ alkyl})< / annotation>< / semantics>< / com:Math>amino, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylacyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylacyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylsulfonyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylsulfonyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkylsulfinyl, C<com:Sub>3-10< / com:Sub> cycloalkylamino, C<com:Sub>3-10< / com:Sub> heterocycloalkylamino, C<com:Sub>3-10< / com:Sub> cycloalkoxy, C<com:Sub>3-10< / com:Sub> cycloalkylacyl, C<com:Sub>3-10< / com:Sub> cycloalkoxyacetyl, C<com:Sub>3-10< / com:Sub> cycloalkylsulfonyl and C<com:Sub>3-10< / com:Sub> cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Or optionally R<com:Sub>2< / com:Sub> and R<com:Sub>2'< / com:Sub> or R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-8< / com:Sub> 6 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each R<com:Sub>d3< / com:Sub>, R<com:Sub>d4< / com:Sub>, R<com:Sub>d5< / com:Sub>, R<com:Sub>d6< / com:Sub>, R<com:Sub>d7< / com:Sub>, R<com:Sub>d8< / com:Sub>, R<com:Sub>d9< / com:Sub> and R<com:Sub>d10< / com:Sub> is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> <com:Sub>10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-< / com:Sub> 10 heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IC), [Image disponible dans le document PDF, Image available in the PDF document] Formula(IC) Wherein, ---- optionally represents a single bond or a double bond; X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)N(Rd3)<annotation encoding="application / x-tex">-C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=NRd5)<annotation encoding="application / x-tex">C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(Rd6)<annotation encoding="application / x-tex">-S(=O)_2N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, - <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> are independently selected from -CR<com:Sub>5< / com:Sub>- or - N-; R<com:Sub>0< / com:Sub> is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R<com:Sub>0< / com:Sub> representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-< / com:Sub> 10 saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> Alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate, preferably, the [Image disponible dans le document PDF, Image available in the PDF document] carboxyl surrogate ; Wherein <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl substituted by <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl or <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> 10 heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH<com:Sub>3< / com:Sub>, Carboxyl, OH, CN and NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>; Or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, <com:Math><semantics>=<annotation encoding="application / x-tex">=< / annotation>< / semantics>< / com:Math>O, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-6< / com:Sub> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> and R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkylamino, N, N- <com:Math><semantics>di(C1−10 alkyl)<annotation encoding="application / x-tex">di(C_{1-10} \text{ alkyl})< / annotation>< / semantics>< / com:Math>amino, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylacyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylacyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylsulfonyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylsulfonyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkylsulfinyl, C<com:Sub>3-10< / com:Sub> cycloalkylamino, C<com:Sub>3-10< / com:Sub> heterocycloalkylamino, C<com:Sub>3-10< / com:Sub> cycloalkoxy, C<com:Sub>3-10< / com:Sub> cycloalkylacyl, C<com:Sub>3-10< / com:Sub> cycloalkoxyacetyl, C<com:Sub>3-10< / com:Sub> cycloalkylsulfonyl and C<com:Sub>3-10< / com:Sub> cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Or optionally R<com:Sub>2< / com:Sub> and R<com:Sub>2'< / com:Sub> or R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-8< / com:Sub> 6 alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each R<com:Sub>d3< / com:Sub>, R<com:Sub>d4< / com:Sub>, R<com:Sub>d5< / com:Sub>, R<com:Sub>d6< / com:Sub>, R<com:Sub>d7< / com:Sub>, R<com:Sub>d8< / com:Sub>, R<com:Sub>d9< / com:Sub> and R<com:Sub>d10< / com:Sub> is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> <com:Sub>10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-< / com:Sub> 10 heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (ID), [Image disponible dans le document PDF, Image available in the PDF document] Wherein, ----- optionally represents a single bond or a double bond; X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)N(Rd3)<annotation encoding="application / x-tex">-C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=NRd5)<annotation encoding="application / x-tex">C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(Rd6)<annotation encoding="application / x-tex">-S(=O)_2N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; preferred <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>2-; preferred <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-or <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N(Rd4)<annotation encoding="application / x-tex">N(R_{d4})< / annotation>< / semantics>< / com:Math>-; X<com:Sub>1< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>13< / com:Sub> are independently selected from –CR<com:Sub>5< / com:Sub>-or - N-; R<com:Sub>0< / com:Sub> is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R<com:Sub>0< / com:Sub> representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-< / com:Sub> 10 saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> Alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate; wherein C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-< / com:Sub> 10 alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, deuterium, halogen, OCH<com:Sub>3< / com:Sub>, carboxyl, OH, CN and NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>; Or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, a hydrogen on the aryl, saturated or the partially saturated cycloalkyl, or heterocycloalkyl is optionally substituted by hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, <com:Math><semantics>=<annotation encoding="application / x-tex">=< / annotation>< / semantics>< / com:Math>O, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> and R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkylamino, N, N- <com:Math><semantics>di(C1−10 alkyl)<annotation encoding="application / x-tex">di(C_{1-10} \text{ alkyl})< / annotation>< / semantics>< / com:Math>amino, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylacyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylacyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkoxy<annotation encoding="application / x-tex">C_{1-10} \text{ alkoxy}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10 alkylsulfonyl<annotation encoding="application / x-tex">C_{1-10} \text{ alkylsulfonyl}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkylsulfinyl, C<com:Sub>3-10< / com:Sub> cycloalkylamino, C<com:Sub>3-10< / com:Sub> heterocycloalkylamino, C<com:Sub>3-10< / com:Sub> cycloalkoxy, C<com:Sub>3-10< / com:Sub> cycloalkylacyl, C<com:Sub>3-10< / com:Sub> cycloalkoxyacetyl, C<com:Sub>3-10< / com:Sub> cycloalkylsulfonyl and C<com:Sub>3-10< / com:Sub> cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Or optionally R<com:Sub>2< / com:Sub> and R<com:Sub>2'< / com:Sub> or R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> Cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - <com:Math><semantics>N(C1−6 alkyl)2<annotation encoding="application / x-tex">N(C_{1-6} \text{ alkyl})_2< / annotation>< / semantics>< / com:Math>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> 6 alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each R<com:Sub>d4< / com:Sub>, R<com:Sub>d8< / com:Sub>, and R<com:Sub>d9< / com:Sub> is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IE), [Image disponible dans le document PDF, Image available in the PDF document] Formula (IE) Wherein, ----- optionally represents a single bond or a double bond; X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)<annotation encoding="application / x-tex">S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; preferred <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math>-; L is independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>C(=O)N(Rd3)<annotation encoding="application / x-tex">C(=O)N(R_{d3})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NRd5)<annotation encoding="application / x-tex">-C(=NR_{d5})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2<annotation encoding="application / x-tex">-S(=O)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(Rd6)<annotation encoding="application / x-tex">N(R_{d6})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd7)<annotation encoding="application / x-tex">-N(R_{d7})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; preferred <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>N(Rd4)<annotation encoding="application / x-tex">N(R_{d4})< / annotation>< / semantics>< / com:Math>-; X<com:Sub>1< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>13< / com:Sub> are independently selected from –CR<com:Sub>5< / com:Sub>-or - N-; R is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> 10 alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-< / com:Sub> saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> Alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate; or any two adjacent R<com:Sub>1< / com:Sub> together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, - OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, -N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, =O, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl. Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-8< / com:Sub> 6 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each Rd1, Rd2, Rd4, Rd8 and Rd is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IF-1) or (IF- 2), [Image disponible dans le document PDF, Image available in the PDF document] Formula (IF-2) Wherein, ---- optionally represents a single bond or a double bond; X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2−;<annotation encoding="application / x-tex">S(=O)_2-;< / annotation>< / semantics>< / com:Math> L is independently selected from <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)O<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-or-<com:Math><semantics>N(Rd4)<annotation encoding="application / x-tex">N(R_{d4})< / annotation>< / semantics>< / com:Math>-; X<com:Sub>1< / com:Sub> and X<com:Sub>8< / com:Sub> are independently selected from –CR<com:Sub>5< / com:Sub>-or- N-; R is independently selected from hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> 10 alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-< / com:Sub> 10 saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C<com:Sub>1-3< / com:Sub> alkyl group, C<com:Sub>1-3< / com:Sub> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> Alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-< / com:Sub> 10 cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> 10 alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and where in the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - <com:Math><semantics>N(C1−6 alkyl)2<annotation encoding="application / x-tex">N(C_{1-6} \text{ alkyl})_2< / annotation>< / semantics>< / com:Math>, oxy, and saturated or partially saturated <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and the <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> 6 alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub>, R<com:Sub>d4< / com:Sub>, R<com:Sub>d8< / com:Sub> and R<com:Sub>d< / com:Sub> is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IG), [Image disponible dans le document PDF, Image available in the PDF document] Formula (IG) Wherein, X and X' are independently selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>S(=O)2−;<annotation encoding="application / x-tex">S(=O)_2-;< / annotation>< / semantics>< / com:Math> L is independently selected from <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)O<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−N(Rd4)<annotation encoding="application / x-tex">-N(R_{d4})< / annotation>< / semantics>< / com:Math>-; X<com:Sub>1< / com:Sub> and X<com:Sub>8< / com:Sub> are each independently selected from –CR<com:Sub>5< / com:Sub>-or- N-; R is independently hydrogen, deuterium, halogen, -CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl, C<com:Sub>1-10< / com:Sub> alkoxy, -NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R representing <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NRd<com:Sub>8< / com:Sub>Rd<com:Sub>9< / com:Sub>, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl group, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH<com:Sub>3< / com:Sub> and OH. Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH<com:Sub>2< / com:Sub>, -COOH or from C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl, C<com:Sub>3-10< / com:Sub> saturated or partially saturated heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>2-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocyclyl, C<com:Sub>1-10< / com:Sub> alkyl substituted with carboxyl or carboxyl surrogate; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl, and C<com:Sub>1-10< / com:Sub> heteroalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C<com:Sub>3-10< / com:Sub> saturated or partially saturated cycloalkyl or heterocyclyl; Each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR<com:Sub>d8< / com:Sub>R<com:Sub>d9< / com:Sub>, NH<com:Sub>2< / com:Sub>, -COOH or C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkenyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocycloalkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R<com:Sub>5< / com:Sub> or R<com:Sub>6< / com:Sub> together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF<com:Sub>3< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, -NH<com:Sub>2< / com:Sub>, -NHC<com:Sub>1-6< / com:Sub> alkyl, - N(C<com:Sub>1-6< / com:Sub> alkyl)<com:Sub>2< / com:Sub>, oxy, and saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl, and the C<com:Sub>1-6< / com:Sub> alkyl and C<com:Sub>1-8< / com:Sub> 6 alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF<com:Sub>3< / com:Sub>, OH, OCH<com:Sub>3< / com:Sub>, OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, saturated or partially saturated C<com:Sub>3-6< / com:Sub> cycloalkyl; Each R<com:Sub>d1< / com:Sub>, R<com:Sub>d2< / com:Sub>, R<com:Sub>d4< / com:Sub>, R<com:Sub>d8< / com:Sub> and R<com:Sub>d< / com:Sub> is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl; wherein, the C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>2-10< / com:Sub> alkynyl or C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>1-10< / com:Sub> alkylacyl, C<com:Sub>1-10< / com:Sub> alkylsulfonyl, C<com:Sub>2-10< / com:Sub> heteroalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, C<com:Sub>3-10< / com:Sub> heterocycloalkyl, C<com:Sub>1-10< / com:Sub> alkyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl, or C<com:Sub>3-10< / com:Sub> heterocyclyl substituted by C<com:Sub>3-10< / com:Sub> cycloalkyl or C<com:Sub>3-10< / com:Sub> heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C<com:Sub>3-10< / com:Sub> saturated or partially substituted saturated cycloalkyl or heterocyclyl; The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof; The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5; t is an integer optionally selected from 0, 1, 2, 3, and 4. According to an embodiment of the present invention, A is selected from unsubstituted or substituted C<com:Sub>6-20< / com:Sub> aryl, 5- to 20- membered heteroaryl; B is selected from unsubstituted or substituted 3- to 20- membered heterocyclyl, 6- to 18- membered spirocyclyl or bridged cyclyl, C<com:Sub>6-20< / com:Sub> aryl; X and X' are the same or different and are independently selected from -C(R<com:Sub>d1< / com:Sub>)(R<com:Sub>d2< / com:Sub>)-, -O-, - S-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(=O)<annotation encoding="application / x-tex">-OC(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-; L is selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>OC(Rd1)(Rd2)<annotation encoding="application / x-tex">OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>O-, -OC(=O)-, -C(=O)-, -S(=O)- or -S(=O)<com:Sub>2< / com:Sub>-; <com:Math><semantics>Rd1<annotation encoding="application / x-tex">R_{d1}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Rd2<annotation encoding="application / x-tex">R_{d2}< / annotation>< / semantics>< / com:Math> are the same or different and optionally independently selected from hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; X<com:Sub>1< / com:Sub>, X<com:Sub>2< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>4< / com:Sub>, X<com:Sub>5< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>9< / com:Sub> are the same or different and are independently selected from -CR<com:Sub>5< / com:Sub>- or -N-; each R<com:Sub>5< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NH<com:Sub>2< / com:Sub>, -COOH, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; <com:Math><semantics>R0<annotation encoding="application / x-tex">R_0< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl unsubstituted or optionally substituted with one, two or more R<com:Sub>01< / com:Sub>; each R<com:Sub>01< / com:Sub> is the same or different and is independently selected from C<com:Sub>3-20< / com:Sub> cycloalkyl, 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more <com:Math><semantics>R02<annotation encoding="application / x-tex">R_{02}< / annotation>< / semantics>< / com:Math>; each <com:Math><semantics>R02<annotation encoding="application / x-tex">R_{02}< / annotation>< / semantics>< / com:Math> is the same or different, and is independently selected from halogen, deuterium, CN, oxo (= O), <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, halogenated <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, CN-<com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl-C<com:Sub>1-10< / com:Sub> alkyl; Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NH<com:Sub>2< / com:Sub>, COOH, C<com:Sub>1-10< / com:Sub> alkyl-COOH or -C<com:Sub>2-10< / com:Sub> alkenyl-COOH unsubstituted or optionally substituted with one, two or more R<com:Sub>11< / com:Sub>; each R<com:Sub>11< / com:Sub> is the same or different and is independently selected from H, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; Each R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> is the same or different, and is independently selected from hydrogen, deuterium, halogen, oxo (=O), C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; Each R<com:Sub>6< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, SH, NH<com:Sub>2< / com:Sub>, -COOH, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> alkynyl, 5- to 14-membered heteroaryl; Rd3, Rd4, Rd5, Rd6, Rd7, Rd8, Rd9 and Rd10 are the same or different and are optionally and independently selected from hydrogen, deuterium, CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH, C<com:Sub>1-10< / com:Sub> alkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; m is an integer optionally selected from 1, 2, 3 and 4; n is an integer optionally selected from 0, 1, 2, 3, 4 and 5; q is an integer optionally selected from 0, 1, 2, 3, 4 and 5. According to an embodiment of the present invention, A is selected from unsubstituted or substituted C<com:Sub>6-14< / com:Sub> aryl, 5- to 14- membered heteroaryl; B is selected from unsubstituted or substituted 3- to 14- membered heterocyclyl, 6- to 18- membered spirocyclyl or bridged cyclyl, C<com:Sub>6-14< / com:Sub> aryl; X and X' are the same or different and are independently selected from -C(R<com:Sub>d1< / com:Sub>)(R<com:Sub>d2< / com:Sub>)-, -O-, - S-; L is selected from <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−OC(Rd1)(Rd2)<annotation encoding="application / x-tex">-OC(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>O-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-; <com:Math><semantics>Rd1<annotation encoding="application / x-tex">R_{d1}< / annotation>< / semantics>< / com:Math> and R<com:Sub>d2< / com:Sub> are the same or different, and are optionally and independently selected from hydrogen, deuterium, C<com:Sub>1-10< / com:Sub> alkyl; X<com:Sub>1< / com:Sub>, X<com:Sub>2< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>4< / com:Sub>, X<com:Sub>5< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>9< / com:Sub> are the same or different, independently selected from -CR<com:Sub>5< / com:Sub>- or -N-; each R<com:Sub>5< / com:Sub> is the same or different, independently selected from hydrogen, deuterium, halogen, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; <com:Math><semantics>R0<annotation encoding="application / x-tex">R_0< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl unsubstituted or optionally substituted with one, two or more R<com:Sub>01< / com:Sub>; each R<com:Sub>01< / com:Sub> is the same or different and is independently selected from C<com:Sub>3-20< / com:Sub> cycloalkyl, 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more <com:Math><semantics>R02<annotation encoding="application / x-tex">R_{02}< / annotation>< / semantics>< / com:Math>; each <com:Math><semantics>R02<annotation encoding="application / x-tex">R_{02}< / annotation>< / semantics>< / com:Math> is the same or different, independently selected from CN, deuterium, oxo (= O), <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>CN−C1−10<annotation encoding="application / x-tex">CN-C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl-<com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl; Each R<com:Sub>1< / com:Sub> is the same or different and independently selected from, halogen, COOH, C<com:Sub>1-10< / com:Sub> alkyl-COOH, -C<com:Sub>2-10< / com:Sub> alkenyl-COOH unsubstituted or optionally substituted with one, two or more R<com:Sub>11< / com:Sub>; each R<com:Sub>11< / com:Sub> is the same or different, independently selected from H, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH<com:Sub>2< / com:Sub>, -COOH, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy; Each R<com:Sub>6< / com:Sub> is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, C<com:Sub>1-10< / com:Sub> alkyl, C<com:Sub>1-10< / com:Sub> alkoxy, C<com:Sub>2-10< / com:Sub> alkynyl, 5- to 14-membered heteroaryl; m is an integer optionally selected from an integer of 1, 2 and 3; n is an integer optionally selected from 0, 1, 2, 3 and 4; q is an integer optionally selected from 0, 1, 2, 3 and 4. According to an embodiment of the present invention, A is selected from phenyl or pyridyl; B is piperidinyl, azetidinyl, phenyl, (1R,5S)-3-azabicyclo[3.2.1]octyl, spirocyclic group or bridged cyclic group; the spirocyclic or the bridged ring contains one or more heteroatoms optionally and independently selected from N, O or S; X and X' are the same or different and are independently selected from CH<com:Sub>2< / com:Sub>, O or S; L can be selected from O, S, NH, CH<com:Sub>2< / com:Sub>, OCH<com:Sub>2< / com:Sub>, CH<com:Sub>2< / com:Sub>O; X<com:Sub>1< / com:Sub>, X<com:Sub>2< / com:Sub>, X<com:Sub>3< / com:Sub>, X<com:Sub>4< / com:Sub>, X<com:Sub>5< / com:Sub>, X<com:Sub>8< / com:Sub> and X<com:Sub>9< / com:Sub> are the same or different and are independently selected from CH, C-F or N R<com:Sub>0< / com:Sub> is selected from C<com:Sub>1-3< / com:Sub> alkyl unsubstituted or substituted with imidazolyl, pyrazolyl, pyrrolyl, azetidinyl, oxetanyl, pyrrolidinyl or cyclopropyl; the imidazolyl, pyrazolyl, pyrrolyl, azetidinyl, oxetanyl, pyrrolidinyl or cyclopropyl may be unsubstituted or substituted with oxo (=O) or C<com:Sub>1-3< / com:Sub> alkyl, CN- C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl-C<com:Sub>1-3< / com:Sub> alkyl; Each R<com:Sub>1< / com:Sub> is the same or different and is independently selected from COOH, F, -C<com:Sub>1-3< / com:Sub> alkyl- COOH, -C<com:Sub>2-3< / com:Sub> alkenyl-COOH; R<com:Sub>2< / com:Sub>, R<com:Sub>2'< / com:Sub> are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (<com:Math><semantics>=<annotation encoding="application / x-tex">=< / annotation>< / semantics>< / com:Math>O), C<com:Sub>1-3< / com:Sub> alkyl; Each R<com:Sub>4< / com:Sub> is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), C<com:Sub>1-3< / com:Sub> alkyl; Each R<com:Sub>6< / com:Sub> is the same or different and is independently selected from hydrogen, deuterium, F, Cl, Br, CN, ethynyl, imidazolyl; m is optionally selected from 1 or 2; n is optionally selected from 0, 1 or 2; q is optionally selected from 0, 1 or 2. [Image disponible dans le document PDF, Image available in the PDF document] According to an embodiment of the present invention, can be selected from the structures shown below: [Image disponible dans le document PDF, Image available in the PDF document] L can be selected from O, S, NH, CH<com:Sub>2< / com:Sub>, OCH<com:Sub>2< / com:Sub>, CH<com:Sub>2< / com:Sub>O; [Image disponible dans le document PDF, Image available in the PDF document] can be selected from the structures shown below: [Image disponible dans le document PDF, Image available in the PDF document] R<com:Sub>0< / com:Sub> can be selected from the structures shown below: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] • [Image disponible dans le document PDF, Image available in the PDF document] R<com:Sub>1< / com:Sub> can be selected from COOH, F, Both R<com:Sub>2< / com:Sub> and R<com:Sub>2< / com:Sub> are H; R<com:Sub>4< / com:Sub> is H, F, methyl; X<com:Sub>8< / com:Sub> is selected from CH or N; X<com:Sub>9< / com:Sub> is selected from CH or N; m is selected from 1 or 2; n is selected from 1 or 2. In one embodiment of the present invention, the above-mentioned compound or a pharmaceutically acceptable salt thereof, or an enantiomer or isotopic variations thereof, is a compound selected from the following structures: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds represented by Formula (I), its pharmaceutically acceptable salts, solvates, enantiomers, and isotopic variations. According to an embodiment of the invention, the pharmaceutical composition is formulated for administration by a route selected from the group consisting of oral, injection, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural. According to an embodiment of the present invention, the pharmaceutical composition is preferably administered orally. The oral dosage form is not particularly limited, and any oral dosage form well known in the art can be used, preferably including tablets, capsules, suspensions or oral solutions and other oral dosage forms known in the art. As an oral dosage form, the dosage standard used is, for example, 500-1500 mg / day, preferably 700-1200 mg / day, preferably 800-1000 mg / day, most preferably 1000 mg / day. The administration time of the pharmaceutical composition according to the present invention may depend on the degree of the disease, preferably at least 1 month, for example, 1, 2, 3, 4, 5, or 6 months, and the longest may be lifelong medication due to the needs of the disease. According to an embodiment of the present invention, the pharmaceutical composition may further comprise pharmaceutically acceptable excipients selected from at least one including but not limited to the following excipients: filler, disintegrant, binder, lubricant, surfactants, flavoring agents, wetting agents, pH regulators, solubilizers or cosolvents, osmotic pressure regulators. Those skilled in the art can easily determine how to select the corresponding excipients and their corresponding amounts according to the needs of specific dosage forms. According to embodiments of the present invention, the pharmaceutical composition may further contain one or more additional therapeutic agents. Another object of the present invention is to provide use of the above-mentioned compounds for manufacturing a medicament for preventing or treating GLP1 / GLP1R signaling pathway related diseases. The GLP1 / GLP1R signaling pathway related diseases include but are not limited to overweight, obesity, diabetes (T1 D and / or T2DM, including prediabetes), idiopathic T1 D (type 1B), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youthful atypical diabetes mellitus (YOAD), maturity-onset diabetes mellitus (MODY), malnutrition-related diabetes mellitus, gestational diabetes mellitus, hyperglycemia, insulin resistance, hepatic insulin resistance, glucose tolerance Impairment, diabetic neuropathy, diabetic nephropathy, renal disease (e.g., acute kidney disease, renal tubular dysfunction, proinflammatory changes in proximal tubules), diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea suspension, obesity (including hypothalamic and monogenic obesity) and associated comorbidities (e.g., osteoarthritis and urinary incontinence), eating disorders (including binge drinking syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndrome), weight gain due to use of other drugs (e.g., steroid and antipsychotic use), hyperglycemia, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, total Increased cholesterol, high-density lipoprotein cholesterol, low- density lipoprotein cholesterol, hyperinsulinemia, NAFLD (including steatosis, NASH, fibrosis, liver cirrhosis, hepatocellular carcinoma and other related diseases), cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction (e.g., necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, Traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial lipids, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease, left ventricular hypertrophy, peripheral artery disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attack, restenosis, sugar Impaired metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcers, ulcerative colitis, hyperapolipoprotein B lipoproteinemia, Alzheimer's disease Prophylaxis or treatment of silent disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome, and addiction treatment (e.g., alcohol and / or drug abuse) and other conditions. The present invention also provides the use of the compound represented by the Formula (I), its pharmaceutically acceptable salts, solvates, enantiomers and isotopic variations, and the pharmaceutical compositions in the prevention and / or treatment of diseases related to GLP1 / GLP1R signaling pathway. The GLP1 / GLP1R signaling pathway-related diseases have the above-mentioned definitions. The present invention also provides a method for preventing and / or treating diseases related to the GLP1 / GLP1R signaling pathway, comprising administering to a patient a preventive or therapeutically effective amount of the compound represented by Formula (I), a pharmaceutically acceptable salt, a solvate, enantiomers and isotopic variations, thereof at least one of the compounds, or administering to the patient a prophylactically or therapeutically effective amount of the above-mentioned pharmaceutical composition. The GLP1 / GLP1R signaling pathway-related diseases have the above-mentioned definitions. In some embodiments, the patient is a mammal, preferably a human. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows comparison curve of the effects of the compounds of the present invention and known drugs on the IPGTT blood sugar of hGLP1R mice. Figure 2 shows comparison of the effects of the compounds of the present invention and known drugs on the insulin-stimulating release of IPGTT in hGLP1R mice. Figure 3 shows comparison curve of the effect of the compounds of the present invention and known drugs on blood glucose of cynomolgus monkey IVGTT. DETAILED DESCRIPTION OF THE INVENTION Definition and Description: <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C7<annotation encoding="application / x-tex">C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C7<annotation encoding="application / x-tex">C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C7<annotation encoding="application / x-tex">C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math>; The term 'alkyl' as used herein refers to a linear or branched chain monovalent hydrocarbon group. Examples include, but are not limited to, methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl, and hexyl. The term 'alkylene' as used herein refers to a linear or branched chain divalent hydrocarbon group of formula -(CH<com:Sub>2< / com:Sub>)n-. Examples include, but are not limited to, ethylene and propylene. The term 'one to more' or 'one to multiple' as used herein refers to more than 1, such as 1, 2, 3, 4, 5 or more. The term 'carbocycle (radical)' or "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, the carbocycle may contain 3 to 20 carbon atoms, preferably 3 to 12 (e.g. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, more preferably 3 to 6 carbon atoms. The carbocycle may be monocyclic or polycyclic, it may be a saturated cycloalkyl or may optionally contain one, two or more double and / or triple bonds in its ring, thereby forming so-called cycloalkenyl or cycloalkynyl. Where carbocycles have multiple rings, the rings can form spiro, fused and bridged ring structures. For example, non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptyl alkenyl, cyclooctyl, cyclooctatetraenyl, etc.; non-limiting examples of polycyclic carbocycles include decalin or isobornyl. The term 'heterocycle (radical)' refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more of the ring atoms is a heteroatom or group of atoms selected from N, O, NH, S, S(O) or S(O)2, but excluding ring parts of -O-O-, -O-S- or -S-S-, the remaining ring atoms are carbon. Preferably 3 to 12 ring atoms, of which 1 to 4 are heteroatoms, are comprised (e.g. 1, 2, 3 and 4); more preferably 3 to 6 ring atoms (e.g. 3, 4, 5, 6). A heterocyclyl group can be attached to the remainder of the molecule through any of the carbon atoms or a nitrogen atom (if present) or an oxygen or sulfur atom (especially in the case of an onium salt formation). The heterocyclyl group may include fused or bridged rings and / or spiro rings. Non-limiting examples of monocyclic heterocyclyl groups include azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, dioxolyl, tetrahydropyranyl, pyrroline, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dithianyl trithianyl, homopiperazinyl, diazepanyl, etc., preferably piperidinyl and pyrrolidinyl. Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls, and may also be benzo-fused heterocyclyls such as dihydroisoquinolinyl. The heterocyclyl may be bicyclic, non-limiting examples of which include hexahydrocyclopento[c]pyrrol-2(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl. Heterocyclyl can also be partially unsaturated, i.e. it can contain one or more double bonds, non-limiting examples of which include dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H- [1,4]thiazinyl. Heterocyclyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkanethio, heterocycloalkylthio, oxo, carboxyl or carboxylate. As used herein, the term 'heteroaryl / heteroaromatic ring' refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 20 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, nitrogen and phosphorus. Heteroaryl is preferably 5- to 10- membered (e.g. 5-, 6- , 7-, 8-, 9- or 10- membered), more preferably 5- or 6- membered. Non-limiting examples of heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl oxazolyl, thiadiazolyl, thi- 4H-pyrazolyl, etc. and their benzo derivatives such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzoyl imidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and their benzo derivatives, such as quinolinyl, quinazolinyl, isoquinolinyl, etc; or azinyl, indozinyl, purinyl, etc., as well as their benzo derivatives; or cinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and / or phenoxazinyl, etc. Heteroaryl / heteroaryl rings may be optionally substituted or unsubstituted, when substituted, the substituents are preferably one, two or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate. Unless otherwise stated, a heterocyclyl, heteroaryl or heteroaryl ring includes all possible isomeric forms thereof, e.g. positional isomers thereof. Thus, for some illustrative non-limiting examples, can be included in its 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12- and etc. (if present) substituted at one, two or more positions, or bonded to other groups, including pyridin-2-yl, pyridin-2-yl, pyridin-3-yl, Pyridin-3-yl, pyridin-4-yl and pyridin-4-yl; thienyl or thienylene includes thien-2-yl, thien-2-yl, thien-3-yl and thien-3 - base; pyrazol-1-yl, pyrazol-3-yl, pyrazol- 4-yl, pyrazol-5-yl. As used herein, the term 'pharmaceutically acceptable' refers to those compounds, materials, compositions and / or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue, without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio. The term 'pharmaceutically acceptable salts' refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral forms of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, ortho Phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid and similar acids; also includes salts of amino acids such as arginine, etc., and salts of organic acids such as glucuronic acid (See Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base or acid addition salts. The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compounds in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents. As used herein, "pharmaceutically acceptable salts" pertain to derivatives of compounds of the present invention wherein the parent compound is modified by salt formation with an acid or salt formation with a base. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid groups such as carboxylic acids, and the like. Pharmaceutically acceptable salts include conventional non-toxic salts such as Na salts, potassium salts, amine salts, quaternary ammonium salts of the parent compound, and the like. Conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids, inorganic and organic bases selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutaric acid Amino acid, glycolic acid, hydrobromic acid, hydrochloric acid, hydroiodide, hydroxy, hydroxynaphthalene, isethionic acid, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, sulfamic acid, p- aminobenzenesulfonic acid, sulfuric acid, tannin, tartaric acid and p-toluenesulfonic acid etc. described inorganic base and organic base are selected from Na, potassium, magnesium, calcium etc. or amine, diethylamine, triethylamine, ethanolamine etc. The pharmaceutically acceptable salts of the present invention can be synthesized from the acid or base containing parent compound by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. In addition to salt forms, the compounds provided herein also exist in prodrug forms. Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the present invention. In addition, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an in vivo environment. Certain compounds of the present invention may exist in unsolvated as well as solvated forms, including hydrated forms. In general, solvated and unsolvated forms are equivalent and are intended to be included within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. As used herein, the term 'solvate' refers to an association of one or more solvent molecules with a compound of the present invention. Solvate-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. Thus, the term 'hydrate' refers to an association in which the solvent molecule is water. Certain compounds of the present invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the present invention. Schematic representations of racemates, ambiscalemic and scalemic or enantiomerically pure compounds herein are from Maehr, J. Chem. Ed. 1985, 62: 114-120. 1985, 62: 114-120. Unless otherwise stated, wedge and dashed bonds are used to indicate the absolute configuration of a stereocenter. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they include E, Z geometric isomers unless otherwise specified. Likewise, all tautomeric forms are included within the scope of the present invention. The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)- isomers, and racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention. Optically active (R)- and (S)-isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure desired enantiomer. Alternatively, when the molecule contains basic functional groups (such as amino groups) or acidic functional groups (such as carboxyl groups), diastereomeric salts are formed with appropriate optically active acids or bases, followed by stepwise steps well known in the art. The diastereoisomers are resolved by crystallization or chromatography, followed by recovery of the pure enantiomers. In addition, separation of enantiomers and diastereomers is usually accomplished by the use of chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (e.g., carbamate formation from amines). The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, compounds may be labeled with radioactive isotopes, such as tritium (<com:Sup>3< / com:Sup>H), iodine-125 (<com:Sup>125< / com:Sup>I) or C-14 (<com:Sup>14< / com:Sup>C). All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention. The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of an active agent as defined herein, does not negatively interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host. Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy. 21st Ed., Lippincott, Williams & Wilkins (2005). When any variable (e.g., R) occurs more than once in the composition or structure of the compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2 R, the group may optionally be substituted with up to two R, and in each case the R has an independent option. In addition, the combination of substituents and / or their variants is allowed only if such a combination will produce a stable compound. When a bond of a substituent could be cross-linked to two atoms on a ring, such substituent may be bonded to any atoms in the ring. Where the listed substituent does not specify through which atom it is connected to the general structure formula including the compound that is not specifically mentioned, the substituent may be bonded through any one of its atoms. The combination of substituents and / or variant thereof is allowed only if such a combination results in a stable compound. The term "halo" or 'halogen' refers to fluorine, chlorine, bromine and iodine. In order to illustrate the disclosure in more detail, the following examples are given, but the scope of the disclosure is not limited thereto. The compounds of the disclosure can be prepared by various synthetic methods well-known to those skilled in the art, including the embodiments described below, the embodiments combing the embodiments described below with other synthetic methods, and equivalent alternatives known to those skilled in the art. Preferred embodiments include but are not limited to those embodiments of the present invention. Unless otherwise specified, all solvents used in the present invention are commercially available, and no further purification is required for use. The reaction is usually carried out using an anhydrous solvent under an inert atmosphere of nitrogen. NMR spectra were measured on a Bruker-Avance-400 (400 MHz) spectrometer and chemical shifts are reported in <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> (ppm). Mass spectrometry was performed with an Agilent 1200 series (plus 6110 / and 1956A) LC / MS or a Shimadzu MS (DAD: SPD-M20A(LC)) and a Shimadzu Micromass 2020 detector. The mass spectrometer is equipped with an electrospray ionization (ESI) source operating in positive and negative modes. Abbreviations used are as follows: aq is aqueous; TLC is thin layer chromatography; RT is room temperature; MeOH is methanol; EtOH is ethanol; EtOAc is ethyl acetate; THF is tetrahydrofuran; eq for equivalent or equivalents; CDI is carbonyldiimidazole; DCM is Dichloromethane; PE is petroleum ether; DIAD is diisopropyl azodicarboxylate; DMF is N,N- dimethylformamide; DMSO is dimethyl sulfoxide; CBz is benzyloxycarbonyl; Boc is tert-butyl; HOAc is acetic acid; Ms is methylsulfonyl: NMP is N-methylpyrrolidone; DMAP is 4- (dimethylamino)pyridine; Boc<com:Sub>2< / com:Sub>O is di-tert-butyl dicarbonate; TFA is trifluoroacetic acid; DIPEA is Diisopropylethylamine; SOCl<com:Sub>2< / com:Sub> is thionyl chloride; CS<com:Sub>2< / com:Sub> is carbon disulfide; TsOH is 4- toluenesulfonic acid; MTBE is tert-butyl methyl ether; FA is formic acid; ACN is acetonitrile; i- PrOH is 2-propanol. Compounds can be named manually or by ChemDraw® software, or if purchased commercially the supplier's catalog name is used. Usually, TLC or LC-MS is used to determine whether the reaction is completed. EXAMPLES In order to illustrate the present invention in more detail, the following examples are given, but the scope of the present invention is not limited thereto. Example 1-1. Synthesis of methyl <com:Math><semantics>(S,E)<annotation encoding="application / x-tex">(S,E)< / annotation>< / semantics>< / com:Math>-3-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(chloromethyl)<annotation encoding="application / x-tex">(chloromethyl)< / annotation>< / semantics>< / com:Math>-1-<com:Math><semantics>(oxetan−2<annotation encoding="application / x-tex">(oxetan-2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ylmethyl)<annotation encoding="application / x-tex">ylmethyl)< / annotation>< / semantics>< / com:Math>-1H- benzo[d]imidazol-6-yl)acrylate (intermediate A-1): 1). (E) Preparation of methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl diethylphosphonateacetate (1 g, 4.76 mmol) in dry THF (10 mL) at 0 °C sodium hydride (60% w / w dispersed in mineral oil, 210 mg, 5.24 mmol) was added. The mixture was stirred at 0 °C for 30 mins, then 3-fluoro-4-nitrobenzaldehyde (885 mg, 5.24 mmol) was added slowly to above mixture, maintaining the reaction temperature around 0 °C. After the addition was completed, the mixture was naturally warmed to room temperature and stirred for 16 hours. Cool to 0 °C, the mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 × 30 mL). The combined organic layer was concentrated in vacuo to give a residue. The residue was subjected to silica gel column chromatography (PE / EA=3 / 1) to obtain methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate (800 mg, 74.8 %yield). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.18(t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math>=8.2 Hz, 1 H), 8.05(d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math>=12.8 Hz, 1 H), 7.80(d, J=8.6 Hz, 1 H), 7.73(d, J=16.0 Hz, 1 H), 6.93(d, J=16.0 Hz, 1 H), 3.76(s, 3 H). 2). Synthesis of methyl (S,E) -3-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate (300 mg, 1.33 mmol), (S)- oxetan-2-ylmethanamine (116 mg, 1.33 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (368 mg, 2.67 mmol) in N,N- dimethylformamide (5 mL) was stirred at room temperature for 16 hours. The mixture was diluted with water (50 mL) and extracted with EA (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 10 mL). The combined organic layers were washed with brine (50 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo to give a residue. The residue was purified by pre-TLC (PE / EA=1 / 1) to give methyl (S,E)-3-(4-nitro-3- ((oxetan-2-ylmethyl)amino)phenyl)acrylate (320 mg, 82.4% yield), LC-MS m / z: 293 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl (S,E)-3-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl (S,E) (4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (Intermediate 2) (320 mg, 1.1 mmol), Fe (173 mg) and NH<com:Sub>4< / com:Sub>Cl (164 mg) in ethanol / water (v: v=10 / 1, 5 mL) was heated to 80 °C and stirred for 16 hours. The reaction mixture was cooled to room temperature, poured into saturated NaHCO<com:Sub>3< / com:Sub> (30 mL), and then extracted with EA (3 × 10 mL). The combined organic layer was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=20 / 1) to obtain methyl (S, E)-3-(4- amino-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (270 mg, 93.7% yield). LC-MS m / z: 263 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 4). Synthesis of methyl (S,E)-3-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazol-6-yl)acrylate (intermediate A-1): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S, E)-3-(4-amino-3-((oxetan-2- ylmethyl)amino)phenyl)acrylate(intermediate 3) in dry THF (5 mL) chloroacetic anhydride (173 mg, 1.01 mmol) was slowly added at 0 °C. The reaction mixture was stirred at 0°C for 30 mins, after which it was heated to 60 °C and stirred for 3 hours. Cooled to room temperature, quenched with water (20 ml) and extracted with EA (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 10 ml). The combined organic layer was directly concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=50 / 1) to obtain methyl (S, E)-3-(2-(chloromethyl)-1-(oxetan-2- ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (intermediate A-1) (240 mg, 81.9% yield). LC-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 321 [M+H]<com:Sup>+< / com:Sup>. Example 1-2. Synthesis of methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5- yl)methyl)amino)-benzoate (Intermediate A-2): 1 1). Synthesis of methyl 3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of (1-ethyl-1H-imidazol-5-yl)methanamine (240 mg, 1.21 mmol) and methyl 3-fluoro-4-nitrobenzoate (241.2 mg, 1.21 mmol) in THF (6 mL) and MeOH (4 mL) TEA (1.2 g, 12.1 mmol) was added. The reaction mixture was warmed to 60 °C and stirred over weekend. The reaction mixture was poured into saturated brine (100 mL) and extracted with EA (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 80 mL). The organic layer was concentrated in vacuo to give a residue. The residue was purified by flash column chromatography on silica gel (eluted with EA / PE=3 / 1) to obtain methyl 3-(((1- ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (320 mg, 87.0% yield). LC-MS m / z: 305 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 2). Synthesis of methyl 4-amino-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (320 mg, 1.05 mmol) in MeOH (10 mL) wet Pd / C (50 mg) was added under N2 atmosphere. The reaction solution was degassed with H<com:Sub>2< / com:Sub> three times, and then raised to 45 °C for 3 hours under H<com:Sub>2< / com:Sub> atmosphere. The mixture was filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by flash column chromatography on silica gel (eluted with <com:Math><semantics>DCM / MeOH=10 / 1<annotation encoding="application / x-tex">DCM / MeOH=10 / 1< / annotation>< / semantics>< / com:Math>) to obtain methyl 4-amino-3-((((1-ethyl-1H-imidazol-5- yl)methyl)amino)methyl)benzoate (270 mg, 93.8% yield). LC-MS m / z: 275 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5- yl)methyl)amino)benzoate (Intermediate A-2): [Image disponible dans le document PDF, Image available in the PDF document] The solution of methyl 4-amino-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (230.0 mg, 0.84 mmol) and 2-chloroacetic anhydride (285.4 mg, 1.68 mmol) in THF (10 mL) was stirred at room temperature for 16 hours. The reaction solution was poured into saturated brine (100 mL) and extracted with DCM (2×80 mL). The combined organic layers were concentrated in vacuo to obtain methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5- yl)methyl)amino)benzoate (230.0 mg, 78.2% yield), LC-MS m / z: 351 [M+H]<com:Sup>+< / com:Sup>. Example 1-3. Synthesis of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-3): 1). Synthesis of methyl (S)-4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] A solution of methyl 3-fluoro-4-nitrobenzoate (4.0 g, 20 mmol) and (S)-oxetan-2- ylmethanamine (1.7 g, 20 mmol) in DMF (40 mL) was added K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (5.5 g, 40 mmol). The reaction was stirred at room temperature for 12 hours. The reaction solution was poured into saturated brine (200 mL) and extracted with ethyl acetate (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 80 mL). The combined organic layers were washed with saturated brine (<com:Math><semantics>2×200 mL<annotation encoding="application / x-tex">2 \times 200 \text{ mL}< / annotation>< / semantics>< / com:Math>), dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain crude product methyl (S)-4-nitro-3-((oxetan-2- ylmethyl)amino)benzoate (5.2 g). LC-MS m / z: 267 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S)- 4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate (5.2 g, 20 mmol) in methanol (50 mL) wet Pd / C (520 mg) was added under N<com:Sub>2< / com:Sub> atmosphere. The mixture was degassed with H<com:Sub>2< / com:Sub> three times, the reaction mixture was stirred at room temperature for 12 hours under H<com:Sub>2< / com:Sub> atmosphere. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to obtain methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (3.9) g, 82.3% yield), LC-MS m / z: 237 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-3): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (1.5 g, 6 mmol) in THF (12 mL) at 0 °C 2-chloroacetic anhydride (1.1 g, 6.6 mmol) was added. The reaction mixture was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo and purified by silica gel column chromatography (EA / PE=1 / 1) to obtain methyl (S)-2- (chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-3) (1.6 g, 90 % yield). LC-MS m / z: 295 [M+H]<com:Sup>+< / com:Sup>. Example 1-4. Synthesis of methyl(E)-3-(4-(2-chloroacetamide)-3-(((1-ethyl-1H- imidazol-5-yl)methyl)amino)-phenyl)acrylate (Intermediate A -4): 1). Synthesis of methyl (E)- 3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4- nitrophenyl)acrylate: [Image disponible dans le document PDF, Image available in the PDF document] TEA (1.80 g, 17.80 mmol, 10.0 eq) was added to a mixture of methyl (E)-3-(3-fluoro-4- nitrophenyl)acrylate (Intermediate 1) (400 mg, 1.78 mmol) and (1-Ethyl-1H-imidazol-5- yl)methanamine (354 mg, 1.78 mmol) in THF (6 mL) and MeOH (4 mL). After stirring uniformly, the reaction mixture was heated to 60 °C and stirred for 48 hours. The resulting mixture was poured into brine (50 mL) and extracted with EA (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 20 mL). The combined organic layer was concentrated in vacuo and then purified by silica gel column chromatography (DCM / MeOH=10 / 1) to obtain methyl (E)- 3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4- nitrophenyl)acrylate (400 mg, 68.1% yield). LC-MS m / z: 331 [M+H]<com:Sup>+< / com:Sup>. 2) Synthesis of methyl (E) -3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4- aminophenyl)acrylate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4- nitrophenyl)acrylate (400 mg, 1.21 mmol), iron powder (203 mg, 3.63 mmol) and NH<com:Sub>4< / com:Sub>Cl (192 mg, 3.62 mmol) in EtOH / H<com:Sub>2< / com:Sub>O (v / v=10 / 1, 5 mL) was raised to 80 °C and stirred for 5 hours. The reaction was cooled to room temperature, poured into saturated NaHCO<com:Sub>3< / com:Sub> solution (30 mL) and extracted with EA (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 10 mL). The combined organic layers were washed with brine (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 10 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=20 / 1) to obtain methyl (E) -3-(3- ((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-aminophenyl)acrylate (60 mg, 16.5% yield). LC- <com:Math><semantics>MS m / z: 301 [M+H]+.<annotation encoding="application / x-tex">MS \text{ m / z: } 301 \text{ [M+H]}^+.< / annotation>< / semantics>< / com:Math> 3). Synthesis of methyl (E)-3-(4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5- yl)methyl)amino)phenyl)-acrylate (Intermediate A-4): [Image disponible dans le document PDF, Image available in the PDF document] - - The mixture of methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4- aminophenyl)acrylate (50 mg, 0.17 mmol) and 2- chloroacetic anhydride (58 mg, 0.34 mmol) in THF (2 mL) was stirred at room temperature for 16 hours. The resulting mixture was poured into brine (10 mL) and extracted with DCM (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 5 mL). The combined organic layer was directly concentrated to give methyl (E)-3-(4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5- yl)methyl)-amino)phenyl)-acrylate (Intermediate A-4) (50 mg, 79.8% yield). LC-MS m / z: 377 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-5. Synthesis of methyl (S)-2-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazol-6-yl)acetate (intermediate A-5) 1). Synthesis of methyl 2-(3-fluoro-4-nitrophenyl)acetate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of 2-(3-fluoro-4-nitrophenyl)acetic acid (800 mg, 4.02 mmol) in methanol (10 mL) at 0 °C thionyl chloride (957 mg, 8.04 mmol) was slowly added. The mixture was stirred at room temperature for 3 hours, then the reaction mixture was quenched with water (50 mL) at 0 °C and then extracted with ethyl acetate (<com:Math><semantics>2×20<annotation encoding="application / x-tex">2 \times 20< / annotation>< / semantics>< / com:Math> mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered to give a filtrate. The filtrate was concentrated in vacuo to obtained methyl 2-(3-fluoro-4-nitrophenyl)acetate (840 mg,98.1% yield). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.13(t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math>=8.2 Hz, 1H), 7.55(dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math>=12.4, 1.6 Hz, 1H), <com:Math><semantics>7.37(dd,J=8.4,1.0Hz,1H),3.90(s,2H),3.65(s,3H).<annotation encoding="application / x-tex">7.37(dd, J = 8.4, 1.0 Hz, 1H), 3.90(s, 2H), 3.65(s, 3H).< / annotation>< / semantics>< / com:Math> 2). Synthesis of methyl (S)-2-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acetate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl 2-(3-fluoro-4-nitrophenyl)acetate (1.05 g, 4.93 mmol), (S)-oxetan-2- ylmethanamine (468 mg, 5.38 mmol) and potassium carbonate (1.35 g, 9.78 mmol) in N, N- dimethylformamide (10 mL) was stirred at room temperature for 3 hours. The resulting mixture was diluted with water (100 mL) and extracted with dichloromethane (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (PE / EA=2 / 1) to obtain methyl (S)-2-(4-nitro)- 3-((oxetan-2- ylmethyl)amino)phenyl)acetate (300 mg,21.9% yield). LC-MS m / z: 280 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl (S)-2-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acetate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S)-2-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (300) mg, 1.07 mmol) in methanol(10 mL) wet Pd / C (116 mg) was added under N<com:Sub>2< / com:Sub> atmosphere solution. The mixture was degassed with H<com:Sub>2< / com:Sub> three times and stirred at room temperature under H<com:Sub>2< / com:Sub> atmosphere (1 atm) for 16 hours. T The reaction solution was filtered, and the filter cake was washed with methanol (50 mL). The filtrate was concentrated in vacuo and then purified by silica gel column chromatography (PE / EA=1 / 1) to obtain methyl (S)-2-(4-amino-3-((oxetan-2- ylmethyl)amino)phenyl) acetate (120 mg, 45.0% yield). LC-MS m / z: 251 [M+H]<com:Sup>+< / com:Sup>. 4). Synthesis of Methyl (S)-2-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H- benzo[d]imidazol-6-yl)acetate (Intermediate) A-5): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S)-2-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (120 mg, 0.48 mmol) in anhydrous THF (5 mL) 2-chloroacetic anhydride (91 mg, 0.53 mmol) was slowly added at 0 °C. The mixture was stirred at 0 °C for 30 min, then heated to 60 °C for 3 h. Cooled to room temperature and quenched with water (20 mL), then extracted with ethyl acetate (2 × 10 mL). The combined organic layers were dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=50 / 1) to obtain methyl (S)-2-(2-(chloromethyl)-1-(oxetane)-2-ylmethyl)-1H- benzo[d]imidazol-6-yl)acetate(Intermediate A-5) (100 mg, 67.6% yield). LC-MS m / z: 309 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-6. Synthesis of methyl 2-(chloromethyl)-1-(1- (cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]-imidazole-6-carboxylate (Intermediate A- 6): 1). Synthesis of (1-(cyanomethyl)cyclopropyl)methanesulfonate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 2-(1-(hydroxymethyl)cyclopropyl)acetonitrile (2.00 g, 18.00 mmol) and triethylamine (4.00 g, 39.25 mmol) in DCM (20 mL) MsCl (3.12 g, 27.23 mmol) was added dropwise at 0 °C. Then the mixture was stirred at 0 °C for 1 hour and then stirred at room temperature for 2 hours. The mixture was diluted with DCM (50 mL) and washed with brine (25 mL). The organic layer were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give (1-(cyanomethyl)cyclopropyl)methanesulfonate (3.26 g, 17.23 mmol). <com:Sup>1< / com:Sup>HNMR(400 MHz, CDCl<com:Sub>3< / com:Sub>)<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.15(s, 2H), 3.08(s, 3H), 2.59(s, 2H), 0.82(d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 4.0 Hz, 4H). 2). Synthesis of 2-(1-(azidomethyl)cyclopropyl)acetonitrile: [Image disponible dans le document PDF, Image available in the PDF document] A solution of (1-(cyanomethyl)cyclopropyl)methanesulfonate (3.32 g, 17.54 mmol) and sodium azide (4.81 g, 73.99 mmol) in N, N-dimethylformamide (20 mL) was heated to 120 °C for 16 hours. The mixture was cooled to room temperature and quenched by the addition of water, extracted with dichloromethane (30 mL x3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtained 2-(1-(azidomethyl)cyclopropyl)acetonitrile (1.60 g, 11.75 mmol, 66.9% yield). <com:Sup>1< / com:Sup>HNMR(400 MHz, CDCl<com:Sub>3< / com:Sub>)<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 3.31(s, 2H), 2.53(s, 2H), 0.70(d, <com:Math><semantics>J=1.2<annotation encoding="application / x-tex">J = 1.2< / annotation>< / semantics>< / com:Math> Hz, 4H). 3). Synthesis of 2-(1-(aminomethyl)cyclopropyl)acetonitrile: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 2-(1-(azidomethyl)cyclopropyl)acetonitrile (1.60 g, 11.75 mmol) in methanol (15 mL) / water (9 mL) tributyl phosphine (7.13 g, 35.24 mmol) was added dropwise at room temperature. The resulting mixture was heated to 65 °C and stirred for 3 hours. The mixture was filtered, and the filter cake was washed with methanol (10 mL). The filtrate was concentrated in vacuo to obtained 2-(1-(aminomethyl)cyclopropyl)acetonitrile (821 mg, 7.45 mmol, 63.5% yield). <com:Sup>1< / com:Sup>HNMR(400 MHz, DMSO-<com:Sub>d6< / com:Sub>)<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 2.39(s, 2H), 2.25(s, 2H), 0.22(t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 2H), 0.17(t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 2H). 4). Synthesis of methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4- nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 3-fluoro-4-nitrobenzoate (300 mg, 1.51 mmol) and 2-(1- (aminomethyl)cyclopropyl)acetonitrile (166 mg, 1.51 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (625 mg, 4.53 mmol) was added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water (15 mL) and then extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (PE / EA=5 / 1) to give methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4-nitrobenzoate (250 mg, 0.86 mmol,57.6% yield). LC-MS m / z: 290 [M+H]<com:Sup>+< / com:Sup>. 5). Synthesis of methyl 4-amino-3-((1- (cyanomethyl)cyclopropyl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4-nitrobenzoate (200 mg, 0.69 mmol) dissolved in methanol (8 mL) zinc powder (449 mg, 6.87 mmol) and acetic acid (415 mg, 6.91 mmol) were added at room temperature. The mixture was stirred at room temperature for 1 hour. The mixture was diluted water(15 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase column chromatography with the following conditions: Column: Spherical C18, 20 - 40 um, 120 g; Mobile Phase A: water (10 mM FA); Mobile Phase B: acetonitrile; Flow rate: 80 mL / min; Gradient: 40% B - 60% B within 20 minutes; detector: 254 nm. The fractions containing desired product were collected at 52% B and concentrated in vacuo to afford compound methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (141 mg, 0.54 mmol, 78.6% yield). LC-MS m / z: 260 [M+H]<com:Sup>+< / com:Sup>. 6). Synthesis of methyl 2-(chloromethyl)-1-(1-(cyanomethyl)cyclopropyl)methyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-6): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (140 mg, 0.54 mmol) in dry THF (5 mL) 2-chloroacetic anhydride (92 mg, 0.54 mmol) was added batchwise at room temperature. The mixture was stirred at 60 °C for 16 hours. The reaction mixture was quenched by water (5 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were combined and washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18, 20- 40 um, 120 g; mobile phase A: water (10 mM FA); mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 20 minutes 40%-60% B; detector: 254 nm). The mobile phase containing the desired product was collected under 50% B mobile phase and then concentrated in vacuo to obtained methyl 2-(chloromethyl)-1-(1-(cyanomethyl)cyclopropyl)methyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-6) (90 mg, 0.54 mmol, 52.5% yield). LC-MS <com:Math><semantics>m / z:318[M+H]+<annotation encoding="application / x-tex">m / z: 318 [M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-7. Synthesis of methyl 4-(2-chloroacetamide)-3-((1- (cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (Intermediate A-7): 1). Synthesis of 2-(1-((5-Bromo-3-fluoro-2- nitrophenyl)amino)methyl)cyclopropyl)acetonitrile: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 5-bromo-1,3-difluoro-2-nitrobenzene(1.00 g, 4.20 mmol) and 2-(1- (aminomethyl)-cyclopropyl)acetonitrile (464.2 mg, 4.21 mmol) in dimethyl sulfoxide (20 mL) N,N-diisopropylethylamine (1.63 g, 12.61 mmol) was added. The mixture was stirred at 70 °C for 4 hours. The reaction mixture was diluted with water(15 mL) and extracted with ethyl acetate (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 30 mL). The combined organic layers were washed with brine (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE / EA=5 / 1) to obtain 2-(1-((5-bromo-3-fluoro-2- nitrophenyl)amino)methyl)-cyclopropyl)acetonitrile (542.0 mg, 1.65 mmol, 39.3% yield). LC- MS m / z: 328, 330 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 2). Synthesis of 2-(1-((2-amino-5-bromo-3- fluorophenyl)amino)methyl)cyclopropyl)acetonitrile: [Image disponible dans le document PDF, Image available in the PDF document] To ·fluoro-2- nitrophenyl)amino)methyl)cyclopropyl)acetonitrile (542.0 mg, 1.65 mmol) in methanol (10 mL) was added zinc powder (1.08 g, 16.52 mmol) and acetic acid (996.0 mg, 16.59 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 20 mL). The combined organic layers were washed with brine <com:Math><semantics>(2×20 mL)<annotation encoding="application / x-tex">(2 \times 20 \text{ mL})< / annotation>< / semantics>< / com:Math>, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography <com:Math><semantics>(PE / EA=2 / 1)<annotation encoding="application / x-tex">(PE / EA=2 / 1)< / annotation>< / semantics>< / com:Math> to obtain 2-(1-((2-amino-5-bromo-3-fluorophenyl)amino)methyl)- cyclopropyl)acetonitrile (358.0 mg, 1.21 mmol, 72.9% yield). LC-MS m / z: 298 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5- fluorobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 2-(1-((2-amino-5-bromo-3- fluorophenyl)amino)methyl)cyclopropyl)acetonitrile (358.0 mg, 1.21 mmol) in N,N- dimethylformamide (3 mL) / methanol (10 mL) triethylamine (366.6 mg, 3.62 mmol) and 1,1'- bisdiphenylphosphinoferrocene palladium dichloride (88.5 mg, 0.12 mmol) were added at room temperature. The mixture was warmed to 90 °C for 16 hours under carbon monoxide atmosphere. Cooled to room temperature, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (30 mL x3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE / EA=1 / 1) to obtain methyl 4- amino-3-((1-(cyanomethyl)cyclopropyl)-methyl)amino)-5-fluorobenzoate (100.0 mg, 0.36 mmol, 29.8% yield), LC-MS m / z: 278 [M+H]<com:Sup>+< / com:Sup>. 4). Synthesis of methyl 4-(2-chloroacetamide)-3-((1- (cyanomethyl)cyclopropyl)methyl)amino)-5-fluoro-benzoate (Intermediate A-7): [Image disponible dans le document PDF, Image available in the PDF document] Α solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5- fluorobenzoate (85.0 mg, 0.31 mmol) in THF (4 mL) 2-chloroacetic anhydride (52.5 mg, 0.31 mmol) was added dropwise at room temperature. The mixture was stirred at 60°C for 16 hours. The mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (3 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase flash chromatography under the following conditions (column: Spherical C18, 20-40 um, 120 g; mobile phase A: water (10 mM FA); mobile phase B: acetonitrile; flow rate: 80 mL / min; Gradient: 40% B - 60% B in 20 minutes; detector: 254 nm). The mobile phase containing the desired product was collected under 52% B mobile phase and concentrated in vacuo to obtain methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (Intermediate A-7) (141 mg, 0.54 mmol, 78.6% yield). LC-MS m / z: 354 [M+H]<com:Sup>+< / com:Sup>. Example 1-8. Synthesis of methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H- benzo[d]imidazole-6-carboxylate (Intermediate A-8) 1). Synthesis of methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl 3-fluoro-4-nitrobenzoate (1.60 g, 8.05 mmol), oxetan-3- ylmethanamine (700 mg, 8.05 mmol) and potassium carbonate (2.22 g, 16.10 mmol) in N, N- dimethylformamide (20 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 2) to obtain methyl 4-nitro-3-((oxetan-3- ylmethyl)amino)benzoate (1.50 g, 70.1% yield). LC-MS m / z: 267 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate (1.50 g, 5.64 mmol) in methanol (30 mL) palladium on carbon (200 mg) was added under N<com:Sub>2< / com:Sub> atmosphere. The resulting mixture was degassed H<com:Sub>2< / com:Sub> three times and stirred at room temperature for 4 hours under H<com:Sub>2< / com:Sub> atmosphere. The reaction was filtered, and the filter cake was washed with methanol (20) mL). The filtrate was concentrated to obtain methyl 4-amino-3-((oxetan-3- ylmethyl)amino)benzoate (1.20 g, 90.2% yield), which was used in the next reaction without purification. LC-MS m / z: 237 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole- 6-carboxylate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate (1.20 g, 5.08) mmol) in dry THF (20 mL) 2-chloroacetic anhydride (869 mg, 5.08 mmol) was added slowly at 0 °C. After stirred at 0°C for 30 minutes, the mixture was heated to 70°C and stirred for 3 hours. The mixture was quenched with water (100 mL) at room temperature and extracted with ethyl acetate (2 × 0 mL). The organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain methyl 2-(chloromethyl)- 1-(oxetan-3-ylmethyl)-1H -benzo[d]imidazole-6-carboxylate (1.00 g, 67.0% yield), LC-MS m / z: 295 [M+H]<com:Sup>+< / com:Sup>. Example 1-9. Synthesis of methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)- 1H-benzo[d]imidazole-6-carboxylate (Intermediate A- 9): 1). Synthesis of methyl 3-((3-methoxy-3-yl)methyl)amino)-4-nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of methyl 3-fluoro-4-nitrobenzoate (2.00 g, 10.00 mmol), (3-methyloxan-3- yl)carboxamide (1.00 g, 10.00 mmol) and potassium carbonate (4.14 g, 30.00 mmol) in N,N- dimethylformamide (20 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=2 / 1) to obtain methyl 3-((3-methoxy-3- yl)methyl)amino)-4-nitrobenzoate (1.96 g, 70.4% yield). LC-MS m / z: 281 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of methyl 4-amino-3-((3-methyloxetan-3-yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] A solution of methyl 3-((3-methoxy-3-yl)methyl)amino)-4-nitrobenzoate (1.96 g, 7.04 mmol) in methanol (20 mL) was added palladium on carbon (400 mg). The resulting mixture was degassed and flushed with hydrogen three times, and then stirred at room temperature for 4 hours. The reaction was filtered, and the filter cake was washed with methanol (20 mL). The filtrate was concentrated to give methyl 4-amino-3-((3-methyloxetan-3- yl)methyl)amino)benzoate (1.55 g, 85.2% yield), which was directly used for the next step without further purification, LC-MS m / z: 251 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)-1H- benzo[d]imidazole-6-carboxy-late(Intermediate A-10): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((3-methyloxetan-3-yl)methyl)amino)benzoate (200 mg, 0.80 mmol) in dry THF (5 mL) 2-chloroacetic anhydride (137 mg, 0.80 mmol) was added dropwise at 0 °C. The mixture was stirred at room temperature for 1 hour. The solvent was removed by concentration in vacuo to give a residue. The residue was added dioxane (5 mL) then heated to 100 °C for 3 hours. The mixture was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (2 × 10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain methyl 2-(chloromethyl)-1-((3- methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxy-late(Inthemediate A-10) (200 mg, 81.2% yield). LC-MS m / z: 309 [M+H]<com:Sup>+< / com:Sup>. Example 1-10. Synthesis of methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H- imidazol-5-yl)methyl)amino)-benzoate (Intermediate A-10): 1). Synthesis of 1,2-dimethyl-1H-imidazole-5-carbaldehyde: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of 5-bromo-1,2-dimethyl-1H-imidazole (500 mg, 2.86 mmol) in dry tetrahydrofuran (10 mL) n-butyllithium (1.26 mL, 3.15 mmol, 2.5M in hexane) was added at - 78 °C. The mixture was stirred at -78 °C for 30 min, then N, N-dimethylformamide (626 mg, 8.58 mmol) was slowly added to the mixture at 0 °C. The mixture was stirred at room temperature for 2 hours. When completion, the reaction was quenched with water (50 mL) at 0 °C and extracted with ethyl acetate (<com:Math><semantics>2×30<annotation encoding="application / x-tex">2 \times 30< / annotation>< / semantics>< / com:Math> mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain 1,2-dimethyl-1H-imidazole-5-carbaldehyde (300 mg, 84.6 yield %), LC-MS m / z: 125 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 2). Synthesis of (E)-N-((1,2-dimethyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2- sulfinamide: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of 1,2-dimethyl-1H-imidazole-5-carbaldehyde (300 mg, 2.42 mmol), 2- methylpropane-2-sulfoxide (439 mg, 3.63 mmol) and tetraisopropyl titanate (2.06 g, 7.26 mmol) in THF (5 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (2 mL) and filtered. The filtrate was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain (E)-N-((1,2-dimethylene) (500 mg, 91.0% yield). LC-MS m / z: 228 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of N-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2- sulfoxide amide: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of (E)-N-((1,2-dimethyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2- sulfoxide amide (500 mg, 2.20 mmol) and boron sodium hydride (167 mg, 4.40 mmol) in methanol (10 mL) was stirred at room temperature for 2 hours. When completion, the reaction was quenched with water (50 mL) at room temperature and extracted with dichloromethane (2 × 20 mL). The combined organic layer was concentrated in vacuo to obtain N-((1,2-dimethyl-1H- imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (400 mg,: 55.3% yield), which was directly used in the next step without further purification. LC-MS m / z: 230 [M+H]<com:Sup>+< / com:Sup>. 4). Synthesis of 1,2-Dimethyl-1H-imidazol-5-yl)methanamine hydrochloride: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of N-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (400 mg, 1.75 mmol) in HCl (5 mL, 3M in MeOH) was stirred at room temperature for 1 hour. The reaction was filtered to give (1,2-dimethyl-1H-imidazol-5-yl)methanamine hydrochloride (200 mg, 57.8% yield). <com:Sup>1< / com:Sup>H NMR(400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>): δ 8.86(s, 2H), 7.63(s, 1H), 4.19(s, 2H), 3.77(s, 3H), 2.63(s, 3H). 5). Synthesis of methyl 3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)-4- nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of (1,2-dimethyl-1H-imidazol-5-yl)methanamine hydrochloride (200 mg, 1.01 mmol) and methyl 3-fluoro-4-nitrobenzoate (201 mg, 1.01 mmol) in THF (3 mL) and methanol (2 mL) triethylamine (510 mg, 5.05 mmol) was added. The mixture was stirred at 60 °C for 3 h. The resulting mixture was poured into brine (50 mL) and extracted with ethyl acetate (2 <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 20 mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain 3-((1,2-dimethyl-1H-imidazol-5- yl)methyl)amino) -4-Nitrobenzoic acid methyl ester (200 mg, 65.1% yield). LC-MS m / z: 305 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 6). Synthesis of methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5- yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (200 mg, 0.66 mmol) in methanol (10 ml) palladium on carbon (20 mg) was added. The resulting mixture was degassed and flushed with hydrogen three times and stirred at room temperature for 3 hours. The reaction mixture was filtered, and washed with methanol (50 mL). The filtrate was concentrated in vacuo to obtain methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5- yl)methyl)amino)benzoate (150 mg, 82.9% yield) that was directly used in the next step without purification. LC-MS m / z: 275 [M+H]<com:Sup>+< / com:Sup>. 7). Synthesis of methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H-imidazol-5- yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] A solution of methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate (150 mg, 0.55 mmol) and 2-chloroacetic anhydride (142 mg, 0.83 mmol) in THF (3 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H- imidazol-5-yl)methyl)-amino)benzoate (150 mg, 77.9% yield), LC-MS m / z: 351 [M+H]<com:Sup>+< / com:Sup>. Example 1-11. Synthesis of methyl 5-(2-chloroacetamide)-6-(1- (cyanomethyl)cyclopropyl)methyl)amino-picolinate: 1). Synthesis of methyl 6-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5- nitropicolinate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 6-chloro-5-nitropicolinate (850 mg, 3.94 mmol) and 2-(1- (aminomethyl) cyclopropyl)acetonitrile (433 mg, 3.94 mmol) in DMSO (10 mL) N,N- diisopropylethylamine (1.52 g, 11.81 mmol) was added. The reaction was stirred at 60 °C for 16 hours. The resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layer was concentrated and purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain methyl 6-((1- (cyanomethyl)cyclopropyl)methyl)amino)-5-nitropicolinate (190 mg,16.7% yield). LC-MS m / z: 291 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of methyl 5-amino-6-((1- (cyanomethyl)cyclopropyl)methyl)amino)picolinate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 6-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-nitropicolinate (190 mg, 0.65 mmol) in methanol (5 mL) zinc powder (428 mg, 6.55 mmol) and acetic acid (393 mg, 6.55 mmol) were added at room temperature and the resulting solution was stirred at room temperature for 2 hours. After completion, the resulting mixture was filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=2 / 1) to obtain methyl 5-amino-6-((1- (cyanomethyl)cyclopropyl)methyl)amino)picolinate (130 mg, 53.7% yield). LC-MS m / z: 261 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 3). Synthesis of methyl 5-(2-chloroacetamide)-6-(1- (cyanomethyl)cyclopropyl)methyl)aminopicolinate (Intermediate A-11): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 5-amino-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate (80 mg, 0.31 mmol) in tetrahydrofuran (5 mL) 2-chloroacetic anhydride (79 mg, 0.46 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain methyl 5-(2- chloroacetamido)-6-(((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate (Intermediate A- 11) (150 mg, 88% yield). LC-MS m / z: 337 [M+H]<com:Sup>+< / com:Sup>. Example 1-12. Synthesis of methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)-3H- imidazo[4,5-b]pyridine-5-carboxylate (Intermediate A-12) [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl (S)-5-amino-6-((oxetan-2-ylmethyl)amino)picolinate (100 mg, 0.42) mmol) in tetrahydrofuran (10 mL) 2-chloroacetic anhydride (101 mg, 0.63 mmol) was added. The reaction mixture was stirred at 60 °C for 3 hours. The resulting mixture was directly concentrated in vacuo to give methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)-3H- imidazo[4,5-b]pyridine-5-carboxylate (Intermediate A-12) (140 mg). Example 1-13. Synthesis of methyl 5-(2-chloroacetamide)-6-(1-ethyl-1H-imidazol-5- yl)methyl)amino-picolinate(Intermediate A-13): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 5-amino-6-((1-ethyl-1H-imidazol-5-yl)methyl)amino)picolinate(150 mg, 0.54 mmol) in THF (5 mL) 2-chloroacetic anhydride (138 mg, 0.82 mmol) was added dropwise. The mixture was stirred at 25°C for 16 hours. Then the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=10 / 1) to obtain methyl 5-(2-chloroacetamide)-6-(1-ethyl-1H- imidazol-5-yl)methyl)amino-picolinate (180 mg, 94.7% yield). LC-MS m / z: 352 [M+H]<com:Sup>+< / com:Sup>. Example 1-14. Synthesis of methyl 4-(2-chloroacetamide)-3-((1- (cyanomethyl)cyclopropyl)methyl)amino)-benzoate (Intermediate A-14): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (500 mg, 1.93 mmol) in THF (5 mL) 2-chloroacetic anhydride (494 mg, 2.89 mmol) was added. The mixture was stirred at room temperature for 2 hours. After completion, the mixture was concentrated and purified by silica gel column chromatography (petroleum ether / ethyl acetate=2 / 1) to obtain methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)- amino)-benzoate (Intermediate A-14) (400 mg, 61.8% yield). LC-MS m / z: 336 [M+H]<com:Sup>+< / com:Sup>. Example 1-15. Synthesis of (S)-N-(4-Bromo-2-fluoro-6-((oxetan-2- ylmethyl)amino)phenyl)-2-chloroacetamide e (Intermediate A-15): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of (S)-5-bromo-3-fluoro-N¹-(oxetan-2-ylmethyl)benzene-1,2-diamine (300 mg, 1.09 mmol) in dry THF(5 mL) 2-chloroacetic anhydride (241 mg, 1.42 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (10 mL) then extracted with ethyl acetate (10 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain (S)-N-(4-bromo-2-fluoro-6-((oxetane- 2-ylmethyl)amino)phenyl)-2-chloroacetamide (230 mg, 59.9% yield). LC-MS m / z: 353 [M+H]<com:Sup>+< / com:Sup>. Example 1-16. Synthesis of N-(4-bromo-2-((1- (cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (Intermediate A-16): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of 2-(1-((2-amino-5-bromo-3- fluorophenyl)amino)methyl)cyclopropyl)acetonitrile (150 mg, 0.50 mmol) in dry THF(5 mL) 2- chloroacetic anhydride (129 mg, 0.76 mmol) was slowly added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (10 mL) then extracted with ethyl acetate (3 × 10 mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether / ethyl acetate=3 / 1) to give N-(4-bromo-2-((1- (cyanomethyl)cyclopropyl))methyl)amino)-6-fluorophenyl) -2-chloroacetamide (218 mg, crude). LC-MS m / z: <com:Math><semantics>376[M+H]+<annotation encoding="application / x-tex">376 [M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-17. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5- yl)methyl)amino)-5-fluorobenzoate (Intermediate A-17): 1). Synthesis of methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5- fluorobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] Potassium acetate (470 mg, 4.80 mmol) and 1,1'-bisdiphenylphosphinoferrocene palladium dichloride (117 mg, 0.16 mmol) were added to a mixture of 5-bromo-N<com:Sup>1< / com:Sup>-((1-ethyl-1H-imidazol- 5-yl)methyl)-3-fluorobenzene-1,2-diamine (500 mg, 1.60 mmol) in methanol(5mL) and N,N- dimethylformamide (5 mL). The mixture was degassed with carbon monoxide three times and stirred at 90 °C for 16 hours under carbon monoxide atmosphere. After completion, the mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL×2). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to give methyl 4-amino-3-((1-ethyl-1H- imidazol-5-yl)methyl)amino)-5-fluorobenzoate (150 mg, 32.1% yield). LC-MS m / z: 293 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 2). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5- yl)methyl)amino)-5-fluorobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5- fluorobenzoate (150 mg, 0.51 mmol) in THF(5 mL) 2-chloroacetic anhydride (176 mg, 1.02 mmol) was slowly added at room temperature. The reaction was stirred at room temperature for 3 hours. After completion, the reaction was quenched with water (30 mL) and extracted with ethyl acetate (2×20 mL). The organic phase was concentrated in vacuo and then purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain methyl 4-(2- chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (130) mg, 69.3% yield). LC-MS m / z: 369 [M+H]<com:Sup>+< / com:Sup>. Example 1-18. Synthesis of methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)- 1H-imidazol-5-yl)-methyl)aminobenzoate (Intermediate A-18); [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5- yl)methyl)aminobenzoate (500 mg, 1.67 mmol) in dry THF (10 mL) chloroacetic anhydride (715 mg, 4.18 mmol) was slowly added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. After completion, the solvent was removed by concentration in vacuo, The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain methyl 4-(2-chloroacetamide)-3-((1- (cyclopropylmethyl)-1H-imidazol-5-yl)-methyl)aminobenzoate (Intermediate A-18) (400 mg, 63.5% yield). LC-MS m / z: 377 [M+H]<com:Sup>+< / com:Sup>. Example 1-19. Synthesis of methyl 2-(chloromethyl)-1-((1-(cyclopropylmethyl)-1H- imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (IntermediateA-19): [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5- yl)methyl)aminobenzoate (500 mg, 1.67 mmol) in dry THF (10 mL) 2-chloroacetic anhydride (715 mg, 4.18 mmol) was added at room temperature solution. The resulting mixture was stirred at room temperature for 2 hours then raised to 60°C stirred overnight. After completion, the solvent was removed by concentration in vacuo and the residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to obtain methyl 2-(chloromethyl)-1-((1- (cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 16.7% yield). LC-MS m / z: 359 [M+H]<com:Sup>+< / com:Sup>. Example 1-20. Synthesis of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole- 6-carboxylate (Intermediate A-20): 1). Synthesis of methyl 3-(methylamino)-4-nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] The solution of methyl 3-fluoro-4-nitrobenzoate (2.00 g, 10.00 mmol) and methylamine (10 mL, 2 M in tetrahydrofuran) in THF (30 mL) was stirred at room temperature for 2 hours. After completion, it was concentrated in vacuo and was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain methyl 3-(methylamino)-4-nitrobenzoate (1.80 g, 85.0% yield). LC-MS m / z: 211 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of methyl 4-amino-3-(methylamino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 3-(methylamino)-4-nitrobenzoate(1.80 g, 8.57 mmol) in methanol (20 mL) was added palladium on carbon (900 mg) at room temperature under N<com:Sub>2< / com:Sub> atmosphere. The resulting mixture was degassed and flushed with hydrogen three times and stirred at room temperature for 3 hours. After completion, the reaction solution was filtered, and the filter cake was washed with methanol (20 mL). The filtrate was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=16 / 9) to obtain methyl 4-amino-3-(methylamino)benzoate (1.2 g,77.8% yield). LC-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 181 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 3). Synthesis of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6- carboxylate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-(methylamino)benzoate (1.2 g, 2.83 mmol) in dry THF(20 mL) was slowly added chloroacetic anhydride (2.27 g, 5.66 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours, then the reaction mixture was heated to 60 °C for 16 hours. After completion, it was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=3 / 1) to obtain methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (1.4 g, 88.2% yield). LC-MS m / z: <com:Math><semantics>239[M+H]+<annotation encoding="application / x-tex">239 [M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-21. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-isopropyl-1H-imidazol- 5-yl)methyl)amino)-benzoate(Intermediate A-21): 1). Synthesis of (E)-N-((1-isopropyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2- sulfoxide amide: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (5.00 g, 25.12 mmol), potassium carbonate (10.40 g, 75.36 mmol) and 2-iodopropane (8.54 g, 50.25 mmol) in N,N-dimethylacetamide (100 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=12 / 1) to give (E)-N-((1- isopropyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (4.8 g, 73.4% yield). LC-MS m / z: 242 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2- sulfoxide amide: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of (E)-N-((1-isopropyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2- sulfoxide amide (4.80 g, 19.92 mmol) in methanol (30 mL) sodium borohydride (2.28 g, 59.75 mmol) was slowly added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. After completion, water (200 mL×2) was added to quench the reaction, and extracted with ethyl acetate (200 mL). The combined organic layers were washed with brine (200 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (4.5 g, 87.5%) yield), LC-MS m / z: 244 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of (1-isopropyl-1H-imidazol-5-yl)methanamine: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (4.50 g, 18.44 mmol) and AcOH (50 mL, 3 M in methanol) was stirred for 16 hours at room temperature. After completion, the reaction mixture was concentrated in vacuo to obtain (1-isopropyl-1H-imidazol-5-yl)methanamine (2.4 g, 93.6% yield). LC-MS m / z: 140 [M+H]<com:Sup>+< / com:Sup>. 4). Synthesis of methyl 3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-4- nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of (1-isopropyl-1H-imidazol-5-yl)methanamine (2.4 g, 17.27 mmol), methyl 3- fluoro-4-nitrobenzoate (4.14 g, 20.72 mmol) and potassium carbonate (4.79 g, 34.53 mmol) in N,N-dimethylformamide (50 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=12 / 1) to obtained methyl 3-((1- isopropyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (1.2 g, 21.9% yield). LC-MS m / z: 319 [M+H]<com:Sup>+< / com:Sup>. 5). Synthesis of methyl 4-amino-3-((1-isopropyl-1H-imidazol-5- yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (1.2 g, 3.78 mmol) in methanol (30 mL) palladium on carbon (600 mg. 5.6 mmol) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 3 hours under H<com:Sub>2< / com:Sub> atmosphere. After completion, filter and wash the filter cake with methanol (50 mL). After the filtrate was concentrated to give a residue in vacuo, the residue was purified by silica gel column chromatography (dichloromethane / methanol=13 / 1) to obtain 4-amino-3-((1-isopropyl-1H- imidazol-5-yl)methyl) amino) methyl benzoate (750 mg, 69.0% yield). LC-MS m / z: 289 <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>. 6). Synthesis of methyl 4-(2-chloroacetamido)-3-((1-isopropyl-1H-imidazol-5- yl)methyl)amino)benzoate: [Image disponible dans le document PDF, Image available in the PDF document] - - To a solution of methyl 4-amino-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (400 mg, 1.39 mmol) in dry THF(8 mL) added chloroacetic anhydride (595 mg, 3.48 mmol) was slowly at room temperature. The reaction was stirred at for 3 hours. After completion, the reaction solution was concentrated in vacuo, The residue was purified by silica gel column chromatography (dichloromethane / methanol=10 / 1) to obtain 4-(2-chloroacetamido)-3-((1- isopropyl-1H)-imidazol-5-yl)methyl)amino)methyl benzoate (450 mg, 88.8% yield). LC-MS <com:Math><semantics>m / z:365[M+H]+<annotation encoding="application / x-tex">m / z: 365 [M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-22. Synthesis of methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)- 1H-imidazol-5-yl)methyl)aminobenzoate (Intermediate A-22): 1). Synthesis of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of 1H-imidazole-5-carbaldehyde (5.00 g, 52.08 mmol) and 2-methylpropane- 2-sulfoxide amide (9.39 g, 78.12 mmol) in THF (100 mL) titanium tetraisopropoxide (44.40 g, 156.25 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, it was diluted with water (100 mL), filtered, and the filter cake was washed with ethyl acetate (150 mL). And the aqueous layer was extracted with ethyl acetate (100 mL×2). The combined organic layers were washed with brine (250 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=12 / 1) to obtain (E)- N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (9.00 g, 86.4% yield). LC-MS m / z: 200 [M+H]<com:Sup>+< / com:Sup>. 2). Synthesis of (E)-N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylene)-2- methylpropane-2-sulfoxide amide: [Image disponible dans le document PDF, Image available in the PDF document] To a mixture of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (3.00 g, 15.10 mmol) and potassium carbonate (6.25 g, 45.30 mmol) in N,N-dimethylformamide (50 mL) (bromomethyl)cyclopropane (4.08 g, 30.20 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (150 mL×3). The combined organic layers were washed with brine (150 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=13 / 1) to give (E)-N-((1-(cyclopropylmethyl)-1H- imidazol-5-yl)methylene-2-methylpropane-2-sulfoxide amide (2.8 g, yield 73.4%). LC-MS m / z: 254 [M+H]<com:Sup>+< / com:Sup>. 3). Synthesis of N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2- methylpropane-2-sulfoxide amide [Image disponible dans le document PDF, Image available in the PDF document] . . To a solution of (E)-N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylene)-2- methylpropane-2-sulfoxide amide (2.80 g, 11.60 mmol) in methanol (20 mL) sodium borohydride (1.26 g, 33.2 mmol) was added slowly. The reaction was stirred at room temperature for 2 hours. After completion, water (200 mL) was added to quench the reaction, and extracted with ethyl acetate (60 mL×3). The combined organic layers were washed with brine (200 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain N- ((1- (Cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (2.55 g, 90.9% yield). LC-MS m / z: 256 [M+H]<com:Sup>+< / com:Sup>. 4). Synthesis of (1- (cyclopropylmethyl) - 1h-imidazol-5-yl) methylamine hydrochloride: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-methylpropane-2- sulfoxide amide (2.55 g, 10.00 mmol) and HCl (30 mL, 3 M in methanol) was stirred for 16 hours at room temperature. After completion, the mixture was concentrated to obtain (1- (cyclopropylmethyl)-1H-imidazol-5-yl)methanamine hydrochloride (1.87 g, 99.3% yield). LC- MS m / z: <com:Math><semantics>152[M+H]+<annotation encoding="application / x-tex">152 [M+H]^+< / annotation>< / semantics>< / com:Math>. 5). Synthesis of methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)-4- nitrobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of (1-(cyclopropylmethyl)-1H-imidazol-5-yl)methanamine hydrochloride (1.87 g, 9.93 mmol), methyl 3-fluoro-4-nitrobenzoate (2.98 g, 14.90 mmol) and potassium carbonate (2.76 g, 19.87 mmol) in N,N-dimethylformamide (30 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL<com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math>3). The combined organic layers were washed with brine (50 mL<com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math>3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=13 / 1) to obtain methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (1.5 g, 45.7% yield). LC-MS m / z: 331 [M+H]<com:Sup>+< / com:Sup>. 6). Synthesis of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5- yl)methyl)aminobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)-4- nitrobenzoate (1.50 g, 4.55 mmol) in methanol (40 mL) palladium on carbon (750 mg) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 4 hours. After completion, the reaction was filtered, and the filter cake was washed with methanol (50 mL). The filtrate was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=13 / 1) to obtain 4-amino-3-((1- (cyclopropylmethyl)-1H-imidazol-5-yl) ) methyl)aminobenz-oate (1.1 g, 80.7% yield). LC-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 301 [M+H]+. 7). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-(cyclopropylmethyl)-1H-imidazol- 5-yl)methyl)-aminobenzoate: [Image disponible dans le document PDF, Image available in the PDF document] To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5- yl)methyl)aminobenzoate (150 mg, 0.50 mmol) in dry THF (5 ml) chloroacetic anhydride (257 mg, 1.50 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol=15 / 1) to obtain methyl 4-(2-chloroacetamide)-3-((1- (cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-aminobenzoate (180 mg, 95.5% yield). LC-MS <com:Math><semantics>m / z:377[M+H]+<annotation encoding="application / x-tex">m / z: 377 [M+H]^+< / annotation>< / semantics>< / com:Math>. Example 1-23. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-5-oxopyrrolidin- 2-yl)methyl)amino-benzoate (Intermediate A-23): 1). Synthesis of dimethyl ethyl-L-glutamate: [Image disponible dans le document PDF, Image available in the PDF document] The mixture of dimethyl L-glutamate hydrochloride (5.00 g, 23.70 mmol) and potassium hydroxide (770 mg, 26.07 mmol) in methanol (100 mL) was stirred for 15 minutes at room temperature. Then acetaldehyde (1.56 g, 35.55 mmol) was added to the above mixture. The resulting mixture was stirred at room temperature for 2 hours. After completion, the reaction was quenched with water (200 mL) at room temperature, and extracted with ethyl acetate (100 mL×2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and ...
Claims
CLAIMS 1. A compound represented by Formula(I), a pharmaceutically acceptable salt, or an enantiomer thereof [Image disponible dans le document PDF, Image available in the PDF document] Formula(I) wherein, [Image disponible dans le document PDF, Image available in the PDF document] ring B represents ----represents a single bond; ring A represents phenyl; X' is <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-; X represents -O-; L represents -O-; each of <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X4<annotation encoding="application / x-tex">X_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>X5<annotation encoding="application / x-tex">X_5< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> independently is <com:Math><semantics>−CR5<annotation encoding="application / x-tex">-CR_5< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−N<annotation encoding="application / x-tex">-N< / annotation>< / semantics>< / com:Math>-; X<com:Sub>9< / com:Sub> represents -N-; <com:Math><semantics>R0<annotation encoding="application / x-tex">R_0< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl substituted with one substituent group; the substituent group is <com:Math><semantics>C3−10<annotation encoding="application / x-tex">C_{3-10}< / annotation>< / semantics>< / com:Math> saturated or partially saturated heterocyclic group, or 5- to 8- membered heteroaryl; wherein the heteroaryl or saturated or partially saturated heterocyclyl is further optionally substituted with one to multiple alkyl; each R<com:Sub>1< / com:Sub> is the same or different and is independently hydrogen, deuterium, halogen, -CN, - COOH, or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, wherein <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl is substituted with one to more H, deuterium and halogen; each R<com:Sub>2< / com:Sub>, R<com:Sub>2< / com:Sub>', R<com:Sub>d1< / com:Sub>, and R<com:Sub>d2< / com:Sub> are the same or different and independently are hydrogen, deuterium, halogen, or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl; each R<com:Sub>4< / com:Sub> is the same or different and independently is hydrogen, deuterium, halogen, or C<com:Sub>1-10< / com:Sub> alkyl; each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> are the same or different and independently are hydrogen, deuterium, halogen, CN, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; the hetero independently is O, N or an isotope thereof; the halogen independently is F, Cl, Br, I or an isotope thereof; m is 1 or 2; n is 0, 1, or 2; q is 0, 1, 2, or 3; provided that the following compounds are not included: [Image disponible dans le document PDF, Image available in the PDF document] 414 CPST Doc: 1397-6740-6871 [Image disponible dans le document PDF, Image available in the PDF document] 2. The compound according to claim 1 further represented by Formula (IE), the pharmaceutically acceptable salt, or the enantiomer thereof, [Image disponible dans le document PDF, Image available in the PDF document] Formula (IE) wherein, ----represents a single bond; X represents -O-; X' represents <com:Math><semantics>−C(Rd1)(Rd2)<annotation encoding="application / x-tex">-C(R_{d1})(R_{d2})< / annotation>< / semantics>< / com:Math>-; L represents -O-; <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> independently are <com:Math><semantics>−CR5<annotation encoding="application / x-tex">-CR_5< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−N<annotation encoding="application / x-tex">-N< / annotation>< / semantics>< / com:Math>-; X<com:Sub>1< / com:Sub> represents -N-; R is 5- to 8-membered heteroaryl, or 3-to 8- membered saturated or partially saturated heterocyclyl, wherein the 5- to 8-membered heteroaryl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple alkyl; each R<com:Sub>1< / com:Sub> is the same or different and independently is hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, halogen-substituted <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, deuterium substituted <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, or -COOH; each R<com:Sub>4< / com:Sub> is the same or different and independently is hydrogen, deuterium, halogen, C<com:Sub>1-10< / com:Sub> alkyl, or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; each R<com:Sub>5< / com:Sub> and R<com:Sub>6< / com:Sub> are the same or different and independently are hydrogen, deuterium, halogen, CN, <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−10<annotation encoding="application / x-tex">C_{2-10}< / annotation>< / semantics>< / com:Math> alkynyl or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkoxy; each R<com:Sub>d1< / com:Sub> and R<com:Sub>d2< / com:Sub> are the same or different and independently are hydrogen, deuterium, halogen, or <com:Math><semantics>C1−10<annotation encoding="application / x-tex">C_{1-10}< / annotation>< / semantics>< / com:Math> alkyl; m is 1 or 2; n is 0, 1, or 2; q is 0, 1, or 2; and t is 0, or 1.
3. The compound according to claim 2, the pharmaceutically acceptable salt, or the enantiomer thereof, wherein the compound is of Formula (A) [Image disponible dans le document PDF, Image available in the PDF document] (A).
4. The compound according to claim 3, the pharmaceutically acceptable salt, or the enantiomer thereof, wherein, R is oxetanyl, imidazolyl, oxetanyl substituted with alkyl or imidazolyl substituted with alkyl.
5. The compound according to claim 2, the pharmaceutically acceptable salt, or the enantiomer thereof, wherein, <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> independently are -CH- or N.
6. The compound according to claim 2, the pharmaceutically acceptable salt, or the enantiomer thereof, wherein, the alkyl is methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl, or hexyl; each R<com:Sub>1< / com:Sub> is the same or different and independently is hydrogen, F, or -COOH; each R<com:Sub>4< / com:Sub> is the same or different and independently is hydrogen, deuterium, F, or methyl; each R<com:Sub>5< / com:Sub> is the same or different and independently is hydrogen, deuterium, or F; and each R<com:Sub>6< / com:Sub> is the same or different and independently is hydrogen, deuterium, halogen, ethynyl, or CN.
7. A compound, a pharmaceutically acceptable salt, or an enantiomer thereof, wherein the compound is: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] • 8. A pharmaceutical composition comprising the compound of any one of claims 1-7, the pharmaceutically acceptable salt, or the enantiomer thereof and a pharmaceutically acceptable carrier.
9. Use of the compound of any one of claims 1-7, the pharmaceutically acceptable salt, or the enantiomer thereof, in the manufacture of a medicament for preventing or treating a glucagon-like peptide-1 / glucagon-like peptide-1 receptor (GLP1 / GLP1R) signaling pathway related disease.
10. The use according to claim 9, wherein, the GLP1 / GLP1R signaling pathway related disease is overweight, diabetes, hyperglycemia, insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea, obesity, eating disorders, weight gain due to use of other drugs, dyslipidemia, hyperinsulinemia, NAFLD, cardiovascular disease, atherosclerosis sclerosis, or peripheral vascular disease.
11. The use according to claim 10, wherein, the diabetes is T1D or T2DM, prediabetes, latent autoimmune diabetes in adults, youthful atypical diabetes mellitus, maturity-onset diabetes mellitus, malnutrition-related diabetes mellitus, or gestational diabetes mellitus; the eating disorder is binge drinking syndrome, bulimia nervosa, or syndromic obesity; the dyslipidemia is hyperlipidemia, hypertriglyceridemia, or increased total cholesterol; and the NAFLD is steatosis, NASH, fibrosis, cirrhosis, or hepatocellular carcinoma.
